busulfan has been researched along with Granulocytic Leukemia, Chronic in 354 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation." | 9.07 | Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992) |
| "An attempt to prevent the blast crisis in chronic myeloid leukemia by the use of pulsed doses of (cytarabine cytosine arabinoside) and lomustine was attempted as a cooperative group study by Cancer and Leukemia Group B." | 9.07 | Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study. ( Brunner, K; Dear, KB; Haurani, F; Holland, JF; Karanas, A; Silver, RT; Weil, M, 1992) |
| "A case of toxic pneumonia due to busulfan is reported in a man aged 65 treated for three years with busulfan for chronic myeloid leukaemia." | 8.78 | [Alveolar opacities and busulfan pneumonia]. ( About, I; Carles, P; Lauque, D; Levenes, H; Mazerolles, C; Pris, J; Pujazon, MC, 1993) |
| " We reviewed our experience using busulfan and cyclophosphamide (CY), instead of TBI, as the preparative regimen for allogeneic BMT to study the incidence and relationship to graft-versus-host disease (GVHD) of post-treatment eosinophilia." | 7.69 | Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. ( Bolwell, BJ; Kalaycioglu, ME, 1994) |
| "The frequency of induced sister chromatid exchange (SCE) as a sensitive parameter for chemotherapy resistance was studied after in vitro treatment with busulfan in four cases of myeloid blast crisis of Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML)." | 7.68 | Biclonal analysis of busulfan-induced sister chromatid exchange in blast crisis of Philadelphia chromosome-positive chronic myeloid leukemia. ( Becher, R; Prescher, G, 1991) |
| "A case is reported of pericardial fibrosis after busulfan treatment in a man with chronic myeloid leukaemia." | 7.67 | Pericardial fibrosis following busulfan treatment. ( de Maat, CE; Terpstra, W, 1989) |
| "Complete bioavailability of i." | 6.70 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. ( Anderlini, P; Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Gajewski, J; Madden, T; Thall, PF; Tran, HT; Wang, X, 2002) |
| "Busulfan cataracts have rarely been reported probably because cataract is regarded as senile and patients treated with Busulfan usually die before cataract appears." | 6.38 | [Cataracts in a patient treated with busulfan (Mablin powder) for eight years]. ( Amemiya, T; Dake, Y; Honda, A, 1993) |
| " Routine dosing on the basis of BSA or AIBW in adults and adolescents does not require a specific accommodation for the obese." | 5.30 | The impact of obesity and disease on busulfan oral clearance in adults. ( Appelbaum, FR; Corneau, B; Gibbs, JP; Gooley, T; Murray, G; Slattery, JT; Stewart, P, 1999) |
| "Diagnosis at time of presentation was refractory anemia with excess of blasts (RAEB) in two patients, RAEB in transformation (RAEB-t) in three, and juvenile chronic myelogenous leukemia (JCML, the pediatric counterpart of adult chronic myelomonocytic leukemia) in the remaining three children." | 5.29 | Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. ( Bonetti, F; Cazzola, M; Locatelli, F; Maserati, E; Paolucci, P; Pedrazzoli, P; Pession, A; Prete, A; Prete, L; Zecca, M, 1994) |
| "A 32-year-old Japanese man with chronic granulocytic leukemia died of respiratory failure." | 5.28 | Pulmonary alveolar proteinosis and disseminated atypical mycobacteriosis in a patient with busulfan lung. ( Hirose, N; Miake, S; Nagata, N; Shigematsu, N; Sueishi, K; Tanaka, K; Watanabe, K; Yoshida, M, 1990) |
| "Thirty-six adults with chronic myelogenous leukemia (CML) in second or greater chronic phase, accelerated phase, or blast crisis underwent marrow or blood stem cell transplantation from an HLA-matched sibling using high-dose thiotepa, busulfan and cyclophosphamide (TBC) as the preparative regimen." | 5.09 | Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. ( Andersson, B; Champlin, R; Deisseroth, AB; Gajewski, J; Giralt, S; Ippoliti, C; Khouri, I; Körbling, M; Lee, MS; Mehra, R; Przepiorka, D; Thall, P; van Besien, K, 1999) |
| " Cyclosporin A and short methotrexate were used for graft-versus-host disease (GVHD) prophylaxis." | 5.08 | Combined transplantation of allogeneic bone marrow and CD34+ blood cells. ( Arseniev, L; Bähre, O; Battmer, K; Berenson, RJ; Casper, J; Diedrich, H; Jacobs, R; Kadar, JG; Kühl, J; Link, H; Poliwoda, H; Schubert, J, 1995) |
| "A national cooperative group trial was conducted in 153 patients with chronic myelogenous leukemia (CML) in chronic phase treated with oral pulse busulfan to determine if oral vitamin A can increase the time to blast crisis and enhance survival of patients." | 5.08 | Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. ( Appelbaum, FR; Balcerzak, SP; Hynes, H; Kopecky, KJ; Meyskens, FL; Samlowski, W, 1995) |
| "Six patients with either acceleration or blast crisis of transformed chronic myeloid leukemia (CML) were treated with high-dose interferon alpha in combination with hydroxyurea." | 5.08 | Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach. ( Heinemann, V; Jehn, U; Pötscher, C, 1995) |
| "The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation." | 5.07 | Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992) |
| " Cyclosporine, methotrexate and prednisone were used for graft-versus-host disease (GVHD) prophylaxis." | 5.07 | Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. ( Angelucci, E; Baronciani, D; Erer, B; Galimberti, M; Gaziev, D; Giardini, C; Lucarelli, G; Polchi, P; Rapa, S; Ripalti, M, 1994) |
| "An attempt to prevent the blast crisis in chronic myeloid leukemia by the use of pulsed doses of (cytarabine cytosine arabinoside) and lomustine was attempted as a cooperative group study by Cancer and Leukemia Group B." | 5.07 | Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study. ( Brunner, K; Dear, KB; Haurani, F; Holland, JF; Karanas, A; Silver, RT; Weil, M, 1992) |
| "In the clinical phase studies, ranimustine showed very excellent responses against chronic myelogenous leukemia, polycythemia vera and thrombocythemia, and moderate responses against lymphoma or myeloma." | 5.06 | [Ranimustine]. ( Masaoka, T, 1990) |
| "A case of toxic pneumonia due to busulfan is reported in a man aged 65 treated for three years with busulfan for chronic myeloid leukaemia." | 4.78 | [Alveolar opacities and busulfan pneumonia]. ( About, I; Carles, P; Lauque, D; Levenes, H; Mazerolles, C; Pris, J; Pujazon, MC, 1993) |
| " All the patients were conditioned with cyclophosphamide and busulfan, and treated with cyclosporin (CsA)/methotrexate (MTX)/mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis." | 3.77 | Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia. ( Cai, Z; Han, X; He, J; Huang, H; Li, L; Lin, M; Luo, Y; Shi, J; Tan, Y; Xie, W; Ye, X; Zhao, Y; Zheng, Y, 2011) |
| "Hydroxyurea has replaced busulfan as first line treatment in CML since it prolongs survival." | 3.77 | Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group. ( Ansari, H; Hehlmann, R; Kister, P; Kolb, HJ; Papakonstantinou, G; Saussele, S; Schenk, M; Seifarth, W; Simon, M; Willer, A, 1994) |
| "All patients were transplanted between 1992 and 1999, were >or= 18 years of age, received either cyclophosphamide/total-body irradiation (TBI) or busulfan/cyclophosphamide conditioning regimens, and received four doses of methotrexate for graft-versus-host disease prophylaxis post-transplant." | 3.72 | Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. ( Bruemmer, B; Lloid, ME; Potter, JD; Robien, K; Schubert, MM; Ulrich, CM, 2004) |
| " Graft-versus-host disease (GVHD) prophylaxis was attempted with cyclosporine A (CYA) and methotrexate." | 3.70 | [Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence]. ( Hirabayashi, N; Ikeda, Y; Ishida, A; Matsuoka, S; Moriki, T; Okamoto, S; Wakui, M; Watanabe, R, 1998) |
| " We reviewed our experience using busulfan and cyclophosphamide (CY), instead of TBI, as the preparative regimen for allogeneic BMT to study the incidence and relationship to graft-versus-host disease (GVHD) of post-treatment eosinophilia." | 3.69 | Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. ( Bolwell, BJ; Kalaycioglu, ME, 1994) |
| "The frequency of induced sister chromatid exchange (SCE) as a sensitive parameter for chemotherapy resistance was studied after in vitro treatment with busulfan in four cases of myeloid blast crisis of Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML)." | 3.68 | Biclonal analysis of busulfan-induced sister chromatid exchange in blast crisis of Philadelphia chromosome-positive chronic myeloid leukemia. ( Becher, R; Prescher, G, 1991) |
| " Overexpression of P-170 without amplification of MDR-1 was found in four of 11 patients with chronic phase CML at diagnosis, seven of 16 patients treated with busulfan or hydroxyurea in chronic phase and four of 15 patients in blast crisis." | 3.68 | The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia. ( Dowding, C; Goldman, J; Paulsen, W; Weide, R, 1990) |
| "To prolong the survival of patients with chronic myeloid leukemia (CML), 19 patients were treated with busulfan to keep their leukocyte counts within normal range by controlling bone marrow hyperplasia." | 3.67 | [A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan]. ( Atogami, S; Itoyama, T; Jinnai, I; Jubashi, T; Kohno, T; Kuriyama, K; Matsuo, T; Nonaka, H; Tomonaga, M; Tsukasaki, K, 1989) |
| "A case is reported of pericardial fibrosis after busulfan treatment in a man with chronic myeloid leukaemia." | 3.67 | Pericardial fibrosis following busulfan treatment. ( de Maat, CE; Terpstra, W, 1989) |
| "Cyclophosphamide (Cy) in combination with busulfan (Bu) or total body irradiation (TBI) is the most commonly used myeloablative conditioning regimen in patients with chronic myeloid leukemia (CML)." | 2.80 | Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. ( Ahn, KW; Aljurf, MD; Alyea, EP; Arora, M; Avalos, BR; Bolwell, BJ; Bredeson, CN; Cahn, JY; Copelan, EA; Cortes, J; Costa, LJ; Fasan, O; Gale, RP; Ghosh, N; Grunwald, MR; Hale, GA; Hamadani, M; Hamilton, BK; Horowitz, MM; Inamoto, Y; Kalaycio, ME; Kamble, RT; Khoury, HJ; Litzow, MR; Loren, AW; Marks, DI; Maziarz, RT; Ramanathan, M; Saber, W; Savani, BN; Schouten, HC; Szer, J; Ustun, C; van Besien, KW; Waller, EK; Weisdorf, DJ; Wirk, B; Zhu, X, 2015) |
| "Gender-related aspects in chronic myeloid leukemia (CML) have not been studied well." | 2.71 | Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. ( Berger, U; Hasford, J; Hehlmann, R; Heimpel, H; Hochhaus, A; Hossfeld, DK; Kolb, HJ; Lahaye, T; Löffler, H; Maywald, O; Pfirrmann, M; Pralle, H; Queisser, W; Reiter, A, 2005) |
| "Complete bioavailability of i." | 2.70 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. ( Anderlini, P; Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Gajewski, J; Madden, T; Thall, PF; Tran, HT; Wang, X, 2002) |
| "The underlying diseases included acute myelogenous leukemia (n = 6), chronic myelogenous leukemia (n = 2), myelodysplastic syndrome (n = 6), and non-Hodgkin's lymphoma (n = 2)." | 2.70 | Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. ( Kami, M; Kanai, S; Kanda, Y; Kato, K; Kawano, Y; Makimoto, A; Matsubara, H; Mineishi, S; Nakai, K; Ogasawara, T; Ohnishi, T; Saito, T; Shoji, N; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H, 2002) |
| " These data suggest that dose adjustment based on first dose PK data could allow uniformity of busulfan dosing for patients receiving SCT." | 2.69 | A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. ( Apperley, J; Craddock, C; Eades, A; Goldman, J; Hassan, M; Kanfer, E; Matthews, J; Nilsson, C; Olavarria, E; Timms, A, 2000) |
| "To assess the dynamics of myelofibrosis more precisely, computation of differences in the degree of fiber density between the first and last examination was carried out." | 2.68 | The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsies. ( Dammasch, J; Diehl, V; Kloke, O; Kvasnicka, HM; Leder, LD; Meuter, BR; Niederle, N; Schmidt, M; Thiele, J; Zirbes, TK, 1995) |
| "In 1994, the Italian and the German Chronic myeloid leukemia (CML) trials comparing interferon-alpha (IFN-alpha) with conventional chemotherapy were published." | 2.68 | Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. ( Anseri, H; Baccarani, M; Hasford, J; Hehlmann, R; Tura, S; Zuffa, E, 1996) |
| "The clinical course of 196 patients with chronic myelocytic leukemia (CML) was studied." | 2.67 | [Evaluation of 196 patients with chronic myeloid leukemia based on a standard prognosis model]. ( Anger, B; Carbonell, F; Ganser, A; Heimpel, H; Robertson, J; Schmeiser, T; Sokal, JE, 1990) |
| "One hundred fifteen patients with chronic myelocytic leukemia (CML) were administered busulphan 4 mg/kg for 4 days and cyclophosphamide 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from histocompatible sibling donors." | 2.67 | Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. ( Atkinson, K; Avalos, B; Biggs, JC; Concannon, AJ; Crilley, P; Dodds, A; Downs, K; Kapoor, N; Szer, J; Tutschka, P, 1992) |
| "One of the MPDs, chronic myeloid leukemia (CML), has the distinct cytogenetic abnormality of the Philadelphia chromosome." | 2.42 | Treatment paradigms in the management of myeloproliferative disorders. ( Fruchtman, SM, 2004) |
| "Several randomized clinical trials in chronic myeloid leukemia (CML) have reported better patient survival with interferon alfa (IFN alpha) than with standard chemotherapeutic agents, such as busulfan or hydroxyurea." | 2.40 | Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. ( , 1997) |
| "Chronic myelogenous leukemia is a clonal disorder of hematopoietic stem cells characterized by granulocytic leukocytosis, splenomegaly, and a specific chromosomal abnormality, the Philadelphia chromosome." | 2.39 | Update on therapy for chronic myelogenous leukemia. ( Weinberger, BB, 1994) |
| " The superiority of a therapeutic regimen in chronic phase CML seems to primarily depend on whether its pharmacology permits a sufficiently high dosage to achieve the necessary reduction of tumor burden." | 2.39 | Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival. ( Hehlmann, R; Heimpel, H, 1996) |
| "Busulfan cataracts have rarely been reported probably because cataract is regarded as senile and patients treated with Busulfan usually die before cataract appears." | 2.38 | [Cataracts in a patient treated with busulfan (Mablin powder) for eight years]. ( Amemiya, T; Dake, Y; Honda, A, 1993) |
| "The technique of high-dose chemotherapy and bone-marrow transplantation takes advantage of any potential dose-response effect in the treatment of cancer and the ability of infused marrow to circumvent severe myelotoxicity." | 2.38 | High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report. ( Boyd, AW; Brodie, GN; Green, MD; Griffiths, JD; McGrath, KM; Russell, DM; Scarlett, JD; Sheridan, WP; Thomas, RJ; Vaughan, SL, 1989) |
| "A 61-year-old male was diagnosed as chronic myelocytic leukemia (CML) in 1985 and had been treated with busulfan for 4 years and 5 months (total 3,572 mg)." | 2.38 | [Busulfan lung exacerbated during steroid therapy: a review of Japanese literature]. ( Hashimoto, M; Hirose, S; Ishikawa, M; Kobayashi, S; Wakabayashi, Y, 1990) |
| "Busulfan is an alkylating agent used in pre-transplant conditioning for patients undergoing hematopoietic stem cell transplantation." | 1.51 | A novel drug interaction between busulfan and blinatumomab. ( Lee, J; Oh, A; Patel, P; Quigley, JG; Rondelli, D; Sweiss, K; Ye, R, 2019) |
| "Busulfan is a widely used chemotherapeutic drug for chronic myelogenous leukemia and bone marrow transplantation." | 1.51 | Melatonin protects spermatogonia from the stress of chemotherapy and oxidation via eliminating reactive oxidative species. ( Lin, Z; Mi, J; Song, H; Sun, Z; Wei, R; Xia, Q; Yang, Y; Zhang, X; Zou, K, 2019) |
| "busulfan (Bu) has been shown to be highly effective as a pretransplant conditioning regimen in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS)." | 1.43 | Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. ( Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL, 2016) |
| "Treatment of imatinib-sensitive, BCR-ABL-positive K562 and LAMA84 cells with nilotinib in combination with mafosfamide, treosulfan, or busulfan resulted in synergistic (CI < 1), additive (CI ~ 1), and predominantly antagonistic (CI > 1) effects, respectively." | 1.40 | In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia. ( Dreger, P; Fruehauf, S; Ho, AD; Jens Zeller, W; Luft, T; Radujkovic, A; Topaly, J, 2014) |
| "Oral lorazepam was tolerated by the patients, but all patients needed dose reduction due to some adverse effects." | 1.36 | Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. ( Amini, M; Ghavamzadeh, A; Hadjibabaie, M; Hamedani, R; Hamidieh, AA; Sadrai, S, 2010) |
| " Non-linear modulating influence was registered even at low dosage of cytostatics which actually could not affect leukemic cell viability." | 1.33 | [Modulating effect of antileukemia drugs on the cellular susceptibility in chronic myeloid leukemia to cytotoxic lymphocytes]. ( Antonenko, EV; Cherepovich, VS; Grinëv, VV; Lotkova, ES; Shakhlevich, EV, 2006) |
| "To investigate the relationship of chromosomal aberrations at blastic crisis (BC) in chronic myelogenous leukemia (CML), with previous therapies and with atomic bomb (AB) exposure, we studied 114 CML patients who developed BC, including 23 AB survivors in Hiroshima." | 1.32 | Effect of interferon-alpha on chromosome abnormalities in treated chronic myelogenous leukemia patients. ( Dohy, H; Ito, K; Ito, T; Kimura, A; Kyo, T; Oguma, N; Tanaka, H; Tanaka, K, 2004) |
| "Treatment with busulfan was stopped in March 1993 due to bone marrow suppression." | 1.32 | Long-term cytogenetic remission with ubenimex monotherapy in a case of chronic myeloid leukemia. ( Fujimaki, K; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Taguchi, J; Takabayashi, M; Takasaki, H; Yamaji, S, 2004) |
| " Adverse effects of IFN were similar in both age groups, but IFN dosage to achieve treatment goals was lower in older patients." | 1.32 | Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. ( Berger, U; Engelich, G; Gnad, U; Hasford, J; Hehlmann, R; Heimpel, H; Heinze, B; Hochhaus, A; Hossfeld, DK; Kolb, HJ; Löffler, H; Maywald, O; Metzgeroth, G; Pfirrmann, M; Pralle, H; Queisser, W; Reiter, A, 2003) |
| "A reciprocal influence between chronic myeloid leukemia and hemophilia appears illustrated by this case report." | 1.31 | [Chronic myeloid leukemia in hemophilia B]. ( Larraín, C, 2002) |
| " Anticipatory changes in hydroxyurea dosage or the maintenance of a constant dose did not abolish periodicity, but a change in therapy to the non-cycle-specific drug anagrelide dampened and abolished the cycling." | 1.31 | Hydroxyurea and periodicity in myeloproliferative disease. ( Bennett, M; Grunwald, AJ, 2001) |
| "Busulfan was not suitable for maintaining treatment." | 1.31 | [Observation of long-term therapeutic outcome in chronic granulocytic leukemia]. ( Hao, C; Liu, B; Liu, Y; Qian, L; Wang, Y, 2001) |
| "We report a 44-yr-old female with Philadelphia chromosome positive chronic myeloid leukemia who was initially treated with busulfan, and clinical remission has been achieved." | 1.31 | Busulfan-induced loss of Ph chromosome in chronic myeloid leukemia. ( Colovic, M; Krtolica, K; Radojkovic, M; Ristic, S; Todoric, B, 2001) |
| "Of the 124 patients without myelofibrosis at onset, 42% later transformed into the myelofibrotic subtype." | 1.31 | Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia. ( Kvasnicka, HM; Leder, LD; Schaefer, HE; Schmitt-Graeff, A; Thiele, J, 2000) |
| "Philadelphia chromosome-positive chronic myelogenous leukemia was diagnosed in a now 37-year old woman 16 years ago." | 1.30 | Chronic myelogenous leukemia in chronic phase for 16 years: ongoing hematological remission and late minor cytogenetic response under minimal interferon maintenance therapy. ( Fiegl, M; Jäger, U; Mitterbauer, G; Pirc-Danoewinata, H; Weltermann, A, 1999) |
| "A 36-year-old man suffering from chronic myeloid leukemia (in chronic phase) was initially treated with busulphan." | 1.30 | Foetal liver infusion in a chronic myeloid leukemia patient with busulphan toxicity. ( Kochupillai, V; Pati, HP; Sharma, S, 1998) |
| "Fifty patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) underwent allogeneic bone marrow transplantation between October 1988 and January 1997." | 1.30 | Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia. ( Goto, S; Hirabayashi, N; Ishii, M; Mitsuma, A; Noda, N; Yuge, M, 1998) |
| " Routine dosing on the basis of BSA or AIBW in adults and adolescents does not require a specific accommodation for the obese." | 1.30 | The impact of obesity and disease on busulfan oral clearance in adults. ( Appelbaum, FR; Corneau, B; Gibbs, JP; Gooley, T; Murray, G; Slattery, JT; Stewart, P, 1999) |
| "Etoposide is one of the few drugs being used in conditioning regimens because of the ease with which its dosage can be escalated by a factor of 6 compared to the normal dose." | 1.29 | The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ( Bewermeier, P; Hossfeld, DK; Kruger, W; Mross, K; Reifke, J; Zander, A, 1996) |
| "A case of hepatocellular carcinoma (HCC), which developed during chemotherapy for chronic myelogenous leukemia (CML), is presented." | 1.29 | Hepatocellular carcinoma with splenic metastasis developing after 16 years of chemotherapy for chronic myelogenous leukemia: a case report. ( Endo, Y; Hara, M; Katoh, M; Murashima, N; Nakajima, M; Takeuchi, K; Yamaguchi, H, 1994) |
| "Thirty-eight patients had chronic myelogenous leukemia (17 patients chronic phase, 13 patients accelerated phase, eight patients blast phase), 19 patients had acute leukemia (second complete remission or relapse) and eight patients had myelodysplasia." | 1.29 | Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. ( Avalos, B; Bolwell, B; Copelan, E; Crilley, P; Gajewski, J; Klein, J; Sahebi, F; Territo, M, 1996) |
| "We proposed a new approach to treat chronic myelogenous leukemia using a combination of busulfan and Bestatin." | 1.29 | [Bestatin therapy of chronic myelogenous leukemia]. ( Saito, Y; Uzuka, Y, 1993) |
| "Pregnancy was diagnosed via a urine pregnancy test and an ultrasound confirmed a viable foetus at 16 weeks." | 1.29 | Pregnancy in a patient receiving busulphan for chronic myeloid leukaemia. ( Ainoon, O; Cheong, SK; Hamidah, NH; Norhaya, MR, 1994) |
| "Treatment of a 74 year old patient with chronic myelogenous leukemia (CML) with busulphan resulted in an abrupt and pronounced decrease of the white blood cell (WBC) count with restoration of normal peripheral blood cell morphology and regression of splenomegaly." | 1.29 | Induction of differentiation of myeloid leukemic cells by busulphan: in vivo and in vitro observations. ( Fibach, E; Michaeli, J; Rachmilewitz, EA, 1993) |
| "Diagnosis at time of presentation was refractory anemia with excess of blasts (RAEB) in two patients, RAEB in transformation (RAEB-t) in three, and juvenile chronic myelogenous leukemia (JCML, the pediatric counterpart of adult chronic myelomonocytic leukemia) in the remaining three children." | 1.29 | Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. ( Bonetti, F; Cazzola, M; Locatelli, F; Maserati, E; Paolucci, P; Pedrazzoli, P; Pession, A; Prete, A; Prete, L; Zecca, M, 1994) |
| "A female patient with chronic myelocytic leukemia (CML) in chronic phase after busulfan and interferon treatment had four different cell lines in her bone marrow." | 1.28 | Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia. ( Casali, M; Di Raimondo, F; Maserati, E; Milone, G; Parrinello, G; Pasquali, F; Truglio, F, 1992) |
| "Bleeding was observed in 57% of patients with OMF, 23% with PV, 20% with chronic phase CML, and 16% with ET." | 1.28 | Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. ( Daum, I; Jamin, H; Schneider, W; Wehmeier, A, 1991) |
| "Splenomegaly and hepatomegaly were present in 90% and 48% respectively." | 1.28 | Chronic granulocytic leukaemia. A study of 160 cases. ( Kumar, L; Maitreyan, V; Majhi, U; Sagar, TG; Shanta, V, 1990) |
| "Busulfan did however cause a small number of DNA strand breaks to be formed in human cells." | 1.28 | In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients. ( Adlakha, A; Cook, CA; Furmanski, P; Gibson, NW; Hincks, JR; Johnson, CS, 1990) |
| "A 47-year-old woman with chronic myelogenous leukemia was treated with daily busulfan (total dose approximately 500 mg) from December 1988 to January 1990." | 1.28 | [A case of pulmonary alveolar proteinosis and disseminated atypical mycobacteriosis complicating chronic myelogenous leukemia]. ( Akagawa, S; Aoki, N; Ishikawa, M; Kumagai, T; Matsubara, O; Miyake, S; Ohdama, S; Takano, S; Umino, T, 1992) |
| "A 32-year-old Japanese man with chronic granulocytic leukemia died of respiratory failure." | 1.28 | Pulmonary alveolar proteinosis and disseminated atypical mycobacteriosis in a patient with busulfan lung. ( Hirose, N; Miake, S; Nagata, N; Shigematsu, N; Sueishi, K; Tanaka, K; Watanabe, K; Yoshida, M, 1990) |
| "A case of chronic myelogenous leukemia (CML) of 10-year survival in described." | 1.28 | [Bone marrow aplasia without blast crisis in a case of CML of 10-year survival]. ( Abe, R; Ishibashi, T; Kariyone, S; Kimura, H; Matsuda, S; Shichishima, T; Shiga, Y; Uchida, T; Yokoyama, A; Yui, T, 1989) |
| " It is worth noting that both the analogs were definitely less toxic to the host mice than busulfan." | 1.27 | Antitumor activity and neutrophil-selective hematopoietic toxicity of busulfan analogs in mice. ( Kato, T; Kawazoe, Y; Kimoto, H; Kohda, K; Ohta, Y; Suzumura, Y, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 120 (33.90) | 18.7374 |
| 1990's | 150 (42.37) | 18.2507 |
| 2000's | 65 (18.36) | 29.6817 |
| 2010's | 19 (5.37) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sweiss, K | 1 |
| Quigley, JG | 1 |
| Oh, A | 1 |
| Lee, J | 1 |
| Ye, R | 1 |
| Rondelli, D | 1 |
| Patel, P | 1 |
| Zhang, X | 1 |
| Xia, Q | 1 |
| Wei, R | 1 |
| Song, H | 2 |
| Mi, J | 1 |
| Lin, Z | 1 |
| Yang, Y | 1 |
| Sun, Z | 1 |
| Zou, K | 1 |
| Zhaleiko, IO | 1 |
| Perekhrestenko, TP | 1 |
| Bilko, DI | 1 |
| Dyagil, IS | 1 |
| Bilko, NM | 1 |
| Radujkovic, A | 1 |
| Luft, T | 1 |
| Dreger, P | 1 |
| Ho, AD | 2 |
| Jens Zeller, W | 1 |
| Fruehauf, S | 3 |
| Topaly, J | 2 |
| Matsumura, I | 1 |
| Copelan, EA | 6 |
| Avalos, BR | 6 |
| Ahn, KW | 1 |
| Zhu, X | 1 |
| Gale, RP | 2 |
| Grunwald, MR | 2 |
| Hamadani, M | 1 |
| Hamilton, BK | 1 |
| Hale, GA | 1 |
| Marks, DI | 1 |
| Waller, EK | 1 |
| Savani, BN | 1 |
| Costa, LJ | 1 |
| Ramanathan, M | 1 |
| Cahn, JY | 2 |
| Khoury, HJ | 1 |
| Weisdorf, DJ | 1 |
| Inamoto, Y | 1 |
| Kamble, RT | 1 |
| Schouten, HC | 1 |
| Wirk, B | 1 |
| Litzow, MR | 1 |
| Aljurf, MD | 1 |
| van Besien, KW | 1 |
| Ustun, C | 1 |
| Bolwell, BJ | 3 |
| Bredeson, CN | 1 |
| Fasan, O | 1 |
| Ghosh, N | 2 |
| Horowitz, MM | 3 |
| Arora, M | 1 |
| Szer, J | 4 |
| Loren, AW | 1 |
| Alyea, EP | 1 |
| Cortes, J | 1 |
| Maziarz, RT | 1 |
| Kalaycio, ME | 1 |
| Saber, W | 1 |
| Plesca, D | 1 |
| Trivedi, J | 1 |
| Alatrash, G | 1 |
| Thall, PF | 3 |
| Valdez, BC | 1 |
| Fox, PS | 1 |
| Ning, J | 1 |
| Garber, HR | 1 |
| Janbey, S | 1 |
| Worth, LL | 1 |
| Popat, U | 1 |
| Hosing, C | 1 |
| Alousi, AM | 1 |
| Kebriaei, P | 1 |
| Shpall, EJ | 1 |
| Jones, RB | 1 |
| de Lima, M | 2 |
| Rondon, G | 1 |
| Chen, J | 2 |
| Champlin, RE | 3 |
| Andersson, BS | 3 |
| Matias, K | 1 |
| Matias, C | 1 |
| Teixeira, H | 1 |
| Freire, AD | 1 |
| Azevedo, A | 1 |
| Deininger, MW | 1 |
| Ruiz-Delgado, GJ | 1 |
| Gutiérrez-Riveroll, KI | 1 |
| Gutiérrez-Aguirre, CH | 1 |
| Gómez-Almaguer, D | 2 |
| Eyzaguirre-Zapata, R | 1 |
| Priesca-Marin, M | 1 |
| González-Carrillo, ML | 1 |
| Ruiz-Argüelles, GJ | 2 |
| Crilley, PA | 1 |
| Dodds, AJ | 1 |
| Stevenson, D | 1 |
| Phillips, G | 1 |
| Elder, P | 1 |
| Nivison-Smith, I | 1 |
| Penza, S | 1 |
| Topolsky, D | 1 |
| Sobecks, R | 1 |
| Kalaycio, M | 1 |
| Naik, S | 1 |
| Wong, R | 1 |
| Arai, S | 1 |
| Brown, J | 1 |
| Laport, G | 1 |
| Lowsky, R | 1 |
| Miklos, D | 1 |
| Shizuru, J | 1 |
| Blume, K | 1 |
| Negrin, R | 1 |
| Johnston, L | 1 |
| Hamidieh, AA | 1 |
| Hamedani, R | 1 |
| Hadjibabaie, M | 1 |
| Amini, M | 1 |
| Sadrai, S | 1 |
| Ghavamzadeh, A | 1 |
| Huang, XJ | 1 |
| Xu, LP | 1 |
| Liu, KY | 1 |
| Liu, DH | 1 |
| Chen, H | 1 |
| Liu, YR | 1 |
| Chen, YH | 1 |
| Han, W | 1 |
| Wang, Y | 2 |
| Majhail, NS | 1 |
| Brazauskas, R | 1 |
| Rizzo, JD | 1 |
| Sobecks, RM | 1 |
| Wang, Z | 1 |
| Bolwell, B | 2 |
| Wingard, JR | 1 |
| Socie, G | 2 |
| Kanda, Y | 2 |
| Sakamoto, K | 1 |
| Ashizawa, M | 1 |
| Sato, M | 1 |
| Terasako, K | 1 |
| Kikuchi, M | 1 |
| Kimura, SI | 1 |
| Okuda, S | 1 |
| Kako, S | 1 |
| Oshima, K | 1 |
| Ding, J | 1 |
| Bao, W | 1 |
| Wang, J | 1 |
| Zhao, G | 1 |
| Luo, Y | 1 |
| Zhao, Y | 1 |
| Tan, Y | 1 |
| Shi, J | 1 |
| Han, X | 1 |
| Zheng, Y | 1 |
| Li, L | 1 |
| He, J | 1 |
| Xie, W | 1 |
| Ye, X | 1 |
| Cai, Z | 1 |
| Lin, M | 1 |
| Huang, H | 1 |
| GRIFONI, V | 1 |
| Garming-Legert, K | 1 |
| Remberger, M | 2 |
| Ringdén, O | 2 |
| Hassan, M | 2 |
| Dahllöf, G | 1 |
| Herberich, E | 1 |
| Hothorn, T | 1 |
| Cho, WK | 1 |
| Lee, JW | 1 |
| Chung, NG | 1 |
| Jung, MH | 1 |
| Cho, B | 1 |
| Suh, BK | 1 |
| Kim, HK | 1 |
| Steensma, DP | 1 |
| Larraín, C | 1 |
| Grochow, LB | 1 |
| Madden, T | 1 |
| Couriel, D | 1 |
| Wang, X | 1 |
| Tran, HT | 1 |
| Anderlini, P | 1 |
| Gajewski, J | 3 |
| Or, R | 2 |
| Shapira, MY | 1 |
| Resnick, I | 1 |
| Amar, A | 1 |
| Ackerstein, A | 1 |
| Samuel, S | 1 |
| Aker, M | 1 |
| Naparstek, E | 1 |
| Nagler, A | 2 |
| Slavin, S | 2 |
| Radich, JP | 1 |
| Gooley, T | 2 |
| Bensinger, W | 1 |
| Chauncey, T | 1 |
| Clift, R | 2 |
| Flowers, M | 1 |
| Martin, P | 2 |
| Slattery, J | 1 |
| Sultan, D | 1 |
| Appelbaum, FR | 7 |
| Othieno-Abinya, NA | 1 |
| Nyabola, LO | 1 |
| Kiarie, GW | 1 |
| Ndege, R | 1 |
| Maina, JM | 1 |
| Bornhauser, M | 4 |
| Storer, B | 1 |
| Slattery, JT | 3 |
| Deeg, HJ | 6 |
| Hansen, J | 1 |
| Martin, PJ | 2 |
| McDonald, GB | 1 |
| Nichols, WG | 1 |
| Radich, J | 2 |
| Woolfrey, A | 1 |
| Jenke, A | 2 |
| Schleyer, E | 1 |
| Thiede, C | 1 |
| Ehninger, G | 5 |
| Anasetti, C | 2 |
| Rák, K | 1 |
| Sohn, SK | 1 |
| Kim, JG | 1 |
| Kim, DH | 1 |
| Lee, KB | 1 |
| Berger, U | 3 |
| Engelich, G | 1 |
| Maywald, O | 2 |
| Pfirrmann, M | 3 |
| Hochhaus, A | 8 |
| Reiter, A | 3 |
| Metzgeroth, G | 1 |
| Gnad, U | 1 |
| Hasford, J | 9 |
| Heinze, B | 8 |
| Heimpel, H | 15 |
| Hossfeld, DK | 9 |
| Kolb, HJ | 10 |
| Löffler, H | 6 |
| Pralle, H | 7 |
| Queisser, W | 6 |
| Hehlmann, R | 17 |
| HADDOW, A | 1 |
| TIMMIS, GM | 1 |
| GALTON, DA | 4 |
| TILL, M | 1 |
| HAUT, A | 2 |
| ALTMAN, SJ | 1 |
| CARTWRIGHT, GE | 3 |
| WINTROBE, MM | 3 |
| LOUIS, J | 1 |
| LIMARZI, LR | 1 |
| BEST, WR | 1 |
| BLACKBURN, EK | 1 |
| KING, GM | 1 |
| SWAN, HT | 1 |
| FROST, JW | 1 |
| JACKSON, CB | 1 |
| HYMAN, GA | 1 |
| GELLHORN, A | 1 |
| SCHILLING, RF | 1 |
| MEYER, OO | 1 |
| GREIG, HB | 1 |
| BEROVIC, R | 2 |
| BUGARSKI, M | 2 |
| KONECNI, J | 2 |
| BEYREDER, J | 2 |
| HERZOG, E | 2 |
| TURESSON, D | 1 |
| NELSON, MG | 2 |
| LOWRY, J | 1 |
| BOHINJEC, J | 1 |
| CASFORD, RS | 1 |
| CLOSON, J | 1 |
| CONTENT, M | 1 |
| WILDHACK, R | 1 |
| UNUGUR, A | 1 |
| SCHULMAN, E | 1 |
| DAMESHEK, W | 3 |
| PETRESCU, M | 1 |
| PAPAZIAN, R | 1 |
| OLARU, C | 1 |
| KANZOW, U | 1 |
| WOLFERS, H | 1 |
| HAYHOE, FG | 2 |
| KOK, D | 1 |
| PAWELSKI, S | 1 |
| SOBCZYNSKA-CZECHOWSKA, Z | 1 |
| DE VRIES, SI | 1 |
| VAN ESSER, JG | 1 |
| GIGANTE, D | 1 |
| BELER, B | 1 |
| ERGUN, N | 1 |
| ESTEVEZ, RA | 1 |
| BETHELL, FH | 1 |
| DOCTOR, VM | 1 |
| BERGSAGEL, DE | 2 |
| SHULLENBERGER, CC | 2 |
| KHURGIN, MI | 1 |
| KHASANOVA, RI | 1 |
| GORELOV, IZ | 2 |
| LIPKOVICH, BI | 2 |
| HAMBSCH, K | 1 |
| HAMMER, O | 1 |
| ABBOTT, WS | 1 |
| PAOLINO, W | 1 |
| BACHI, C | 1 |
| PLATZER, S | 1 |
| XEFTERIS, E | 1 |
| MITUS, WJ | 1 |
| MEDNICOFF, IB | 1 |
| COERS, RJ | 1 |
| DUCACH, G | 1 |
| GRANIC, J | 1 |
| TORIELLO, G | 1 |
| UBILLA, V | 1 |
| DURANTE, N | 1 |
| SOLOVEI, DIa | 1 |
| IAVORKOVSKII, LI | 1 |
| SVOBODA, V | 3 |
| UMEGAKI, Y | 1 |
| WATANABE, I | 1 |
| VAKULENKO, AD | 1 |
| WALLER, U | 1 |
| ANTIC, M | 1 |
| RADOJEVIC, B | 1 |
| BRIDGES, JM | 1 |
| HAYES, DM | 1 |
| ECKHARDT, S | 1 |
| SELLEI, C | 1 |
| HARTAI, F | 1 |
| EHRHART, H | 1 |
| GRAF, F | 1 |
| TAKACSI-NAGY, L | 1 |
| HELBIG, W | 1 |
| WEISSEL, M | 1 |
| SHVEDOV, NIa | 1 |
| TOUGH, IM | 2 |
| COURT BROWN, WM | 1 |
| BAIKIE, AG | 1 |
| HARNDEN, DG | 1 |
| JACOBS, PA | 1 |
| WILLIAMS, JA | 1 |
| POGOSIAN, AS | 1 |
| ANGUS, HB | 1 |
| GUNZ, FW | 1 |
| BLOCK, JB | 1 |
| CARBONE, PP | 2 |
| OPPENHEIM, JJ | 1 |
| FREI, E | 2 |
| BALGOZHINA, SZ | 1 |
| TJIO, JH | 1 |
| WHANG, J | 1 |
| GRIZZLE, JE | 1 |
| RITZ, ND | 2 |
| PURFAR, M | 1 |
| HAMMOUDA, F | 1 |
| QUAGLINO, D | 1 |
| FROMMEYER, WB | 1 |
| INAI, S | 1 |
| FUJIKAWA, K | 1 |
| MASAOKA, T | 2 |
| TAKAHASHI, H | 1 |
| NAGAKI, K | 1 |
| SPASSKII, OV | 1 |
| COURTBROWN, WM | 1 |
| KYLE, RA | 1 |
| MURTHY, BG | 1 |
| SWISHER, SN | 1 |
| TROUP, SB | 1 |
| JUNG, F | 1 |
| BLATNIK, D | 1 |
| JUNG, M | 1 |
| NICOLAU, CT | 1 |
| POPESCU, ER | 1 |
| NICOARA, ST | 1 |
| WECHSLER, B | 1 |
| BUTOIANU, E | 1 |
| TAIGAR, S | 1 |
| VERMONT, I | 1 |
| EUGENIU, A | 1 |
| GIORGIU, T | 1 |
| PEDERSEN, B | 1 |
| VIDEBAEK, A | 1 |
| BANERJEA, JC | 1 |
| MUKHERJEE, SK | 1 |
| LOEB, V | 1 |
| DOUGAN, L | 1 |
| WOODLIFF, HJ | 1 |
| TALVALKAR, GV | 1 |
| HARRAP, KR | 1 |
| SPEED, DE | 1 |
| ATHENS, JW | 1 |
| RAAB, SO | 1 |
| HAAB, OP | 1 |
| BOGGS, DR | 1 |
| ASHENBRUCKER, H | 1 |
| GALLAGHER, TF | 1 |
| HELLMAN, L | 1 |
| ZUMOFF, B | 1 |
| MILLER, DG | 1 |
| PETERS, RL | 1 |
| HUNSTEIN, W | 1 |
| HARWERTH, HG | 1 |
| RAJU, S | 1 |
| BALGOZHINA, ShZh | 1 |
| LINQUETTE, M | 1 |
| MESMACQUE, R | 1 |
| FOSSATI, P | 1 |
| GASNAULT, JP | 1 |
| KLIMA, R | 1 |
| MOROZOVA, VT | 1 |
| PEST, R | 1 |
| KRIM, M | 1 |
| LIVSHITS, RA | 1 |
| Buesche, G | 1 |
| Hecker, H | 1 |
| Schmeil, A | 1 |
| Gomez, G | 1 |
| Tobler, A | 2 |
| Herrmann, H | 1 |
| Kappler, M | 1 |
| Buhr, T | 1 |
| Kreipe, HH | 1 |
| Georgii, A | 4 |
| Gómez-Casares, MT | 1 |
| Vaqué, JP | 1 |
| Lemes, A | 1 |
| Molero, T | 1 |
| Delgado, MD | 1 |
| León, J | 1 |
| Robien, K | 1 |
| Schubert, MM | 1 |
| Bruemmer, B | 1 |
| Lloid, ME | 1 |
| Potter, JD | 1 |
| Ulrich, CM | 1 |
| Volkova, SA | 1 |
| Prytkova, MV | 1 |
| Borovkov, NN | 1 |
| Fruchtman, SM | 1 |
| Kanamori, H | 1 |
| Takasaki, H | 1 |
| Takabayashi, M | 1 |
| Yamaji, S | 1 |
| Koharazawa, H | 1 |
| Fujimaki, K | 1 |
| Taguchi, J | 1 |
| Ishigatsubo, Y | 1 |
| Tanaka, H | 1 |
| Tanaka, K | 2 |
| Oguma, N | 1 |
| Ito, K | 1 |
| Ito, T | 2 |
| Kyo, T | 1 |
| Dohy, H | 3 |
| Kimura, A | 1 |
| Olsson-Strömberg, U | 1 |
| Simonsson, B | 2 |
| Ahlgren, T | 1 |
| Björkholm, M | 1 |
| Carlsson, K | 1 |
| Gahrton, G | 1 |
| Hast, R | 1 |
| Löfvenberg, E | 1 |
| Linder, O | 1 |
| Ljungman, P | 1 |
| Malm, C | 1 |
| Paul, C | 1 |
| Rödjer, S | 1 |
| Turesson, I | 1 |
| Udén, AM | 1 |
| Wahlin, A | 1 |
| Killander, A | 1 |
| Wadman, B | 1 |
| Westin, J | 1 |
| Vikrot, O | 1 |
| Zettervall, O | 1 |
| Oberg, G | 1 |
| Singhal, N | 1 |
| Bapsy, PP | 1 |
| Babu, KG | 1 |
| George, J | 1 |
| Lahaye, T | 1 |
| Lokeshwar, N | 1 |
| Kumar, L | 2 |
| Kumari, M | 1 |
| Kröger, N | 3 |
| Schwerdtfeger, R | 2 |
| Schafer-Eckart, K | 1 |
| Sayer, HG | 2 |
| Scheid, C | 1 |
| Stelljes, M | 1 |
| Kienast, J | 1 |
| Mundhenk, P | 1 |
| Kiehl, MG | 1 |
| Wandt, H | 1 |
| Theuser, C | 2 |
| Zander, AR | 2 |
| Jia, YQ | 1 |
| Liu, T | 1 |
| Xu, CG | 1 |
| Niu, T | 1 |
| Meng, WT | 1 |
| Lu, JC | 1 |
| Wang, H | 1 |
| Leng, YM | 1 |
| Krejci, M | 1 |
| Mayer, J | 1 |
| Doubek, M | 1 |
| Brychtova, Y | 1 |
| Pospisil, Z | 1 |
| Racil, Z | 1 |
| Dvorakova, D | 1 |
| Lengerova, M | 1 |
| Horky, O | 1 |
| Koristek, Z | 1 |
| Dolezal, T | 1 |
| Vorlicek, J | 1 |
| Cherepovich, VS | 1 |
| Shakhlevich, EV | 1 |
| Antonenko, EV | 1 |
| Lotkova, ES | 1 |
| Grinëv, VV | 1 |
| Habib, S | 1 |
| Nalesnik, MA | 1 |
| Ahmad, J | 1 |
| BuchBarker, D | 1 |
| Shakil, AO | 1 |
| Chen, MH | 1 |
| Chiou, TJ | 1 |
| Lin, PC | 1 |
| Gau, JP | 1 |
| Hsu, HC | 1 |
| Hsiao, LT | 1 |
| Liu, JH | 1 |
| Chen, PM | 1 |
| Busuttil, DP | 1 |
| Holowiecki, J | 1 |
| Giebel, S | 1 |
| Wojnar, J | 1 |
| Krawczyk-Kulis, M | 1 |
| Markiewicz, M | 1 |
| Holowiecka-Goral, A | 1 |
| Freund, M | 2 |
| Casper, J | 2 |
| Körbling, M | 2 |
| Burke, P | 1 |
| Braine, H | 1 |
| Elfenbein, G | 1 |
| Santos, G | 1 |
| Kaizer, H | 1 |
| Clift, RA | 4 |
| Buckner, CD | 3 |
| Thomas, ED | 3 |
| Bryant, E | 2 |
| Bensinger, WI | 3 |
| Bowden, R | 2 |
| Doney, KC | 2 |
| Fisher, LD | 2 |
| Thiele, J | 9 |
| Kvasnicka, HM | 8 |
| Niederle, N | 5 |
| Zirbes, TK | 3 |
| Schmidt, M | 2 |
| Dammasch, J | 2 |
| Meuter, BR | 1 |
| Leder, LD | 6 |
| Kloke, O | 1 |
| Diehl, V | 6 |
| Griesshammer, M | 4 |
| Link, H | 3 |
| Arseniev, L | 1 |
| Bähre, O | 1 |
| Berenson, RJ | 1 |
| Battmer, K | 1 |
| Kadar, JG | 1 |
| Jacobs, R | 1 |
| Kühl, J | 1 |
| Schubert, J | 1 |
| Diedrich, H | 1 |
| Poliwoda, H | 2 |
| Meyskens, FL | 1 |
| Kopecky, KJ | 1 |
| Balcerzak, SP | 1 |
| Samlowski, W | 1 |
| Hynes, H | 1 |
| Cony-Makhoul, P | 2 |
| Marit, G | 2 |
| Boiron, JM | 1 |
| Puntous, M | 1 |
| Reiffers, J | 2 |
| Kitagawa, S | 1 |
| Saito, M | 1 |
| Miura, Y | 3 |
| Ohnishi, K | 2 |
| Ohno, R | 2 |
| Tomonaga, M | 3 |
| Kamada, N | 4 |
| Onozawa, K | 2 |
| Kuramoto, A | 3 |
| Mizoguchi, H | 2 |
| Miyawaki, S | 2 |
| Tsubaki, K | 2 |
| Ohtsuka, E | 1 |
| Kikuchi, H | 1 |
| Abe, Y | 1 |
| Moriyama, K | 1 |
| Ohno, E | 1 |
| Hirota, K | 1 |
| Tezono, K | 1 |
| Nasu, M | 1 |
| Ansari, H | 4 |
| Adelberger, V | 1 |
| Hossfeld, K | 1 |
| Devergie, A | 3 |
| Blaise, D | 2 |
| Attal, M | 1 |
| Tigaud, JD | 1 |
| Jouet, JP | 1 |
| Vernant, JP | 1 |
| Bordigoni, P | 1 |
| Ifrah, N | 1 |
| Dauriac, C | 1 |
| Savage, DG | 2 |
| Goldman, JM | 9 |
| Hashimoto, T | 1 |
| Ohtaki, M | 1 |
| Ueoka, H | 1 |
| Munaka, M | 1 |
| Weinberger, BB | 1 |
| Kalaycioglu, ME | 1 |
| Kantarjian, HM | 2 |
| Talpaz, M | 3 |
| Norhaya, MR | 1 |
| Cheong, SK | 1 |
| Hamidah, NH | 1 |
| Ainoon, O | 1 |
| Shepherd, PC | 4 |
| Richards, S | 1 |
| Allan, NC | 5 |
| O'Riordan, JM | 1 |
| FitzSimon, S | 1 |
| O'Connor, M | 1 |
| McCann, SR | 2 |
| Abdulkadyrov, KM | 3 |
| Rukavitsyn, OA | 3 |
| Moiseev, SI | 1 |
| Rugal', VI | 1 |
| Amikam, D | 1 |
| Henig, C | 1 |
| Sharon, R | 1 |
| Tatarsky, I | 1 |
| Ben-Ishai, Z | 1 |
| Dexter, TM | 1 |
| Chang, J | 1 |
| Hansen, JA | 1 |
| Tura, S | 4 |
| Baccarani, M | 2 |
| Zuffa, E | 2 |
| Russo, D | 1 |
| Fanin, R | 1 |
| Zaccaria, A | 1 |
| Fiacchini, M | 1 |
| Klein, JL | 2 |
| Kapoor, N | 3 |
| Soysal, T | 1 |
| Bavunoğlu, I | 1 |
| Başlar, Z | 1 |
| Aktuğlu, G | 1 |
| Kister, P | 1 |
| Willer, A | 2 |
| Simon, M | 1 |
| Schenk, M | 1 |
| Seifarth, W | 1 |
| Papakonstantinou, G | 1 |
| Saussele, S | 1 |
| Katoh, M | 1 |
| Takeuchi, K | 1 |
| Murashima, N | 1 |
| Nakajima, M | 1 |
| Yamaguchi, H | 1 |
| Endo, Y | 1 |
| Hara, M | 1 |
| Locatelli, F | 1 |
| Pession, A | 1 |
| Bonetti, F | 1 |
| Maserati, E | 2 |
| Prete, L | 1 |
| Pedrazzoli, P | 1 |
| Zecca, M | 1 |
| Prete, A | 1 |
| Paolucci, P | 1 |
| Cazzola, M | 1 |
| Franco, E | 1 |
| Alvarez, R | 1 |
| Cuesta, I | 1 |
| Aguilar, C | 1 |
| Galimberti, M | 1 |
| Polchi, P | 1 |
| Lucarelli, G | 1 |
| Angelucci, E | 1 |
| Baronciani, D | 1 |
| Giardini, C | 1 |
| Gaziev, D | 1 |
| Erer, B | 1 |
| Ripalti, M | 1 |
| Rapa, S | 1 |
| Aken'Ova, YA | 1 |
| Campbell, OB | 1 |
| Shibata, A | 2 |
| Iurlo, A | 3 |
| Foa, P | 3 |
| Sala, M | 1 |
| Maiolo, AT | 2 |
| Queisser, WP | 1 |
| Essers, U | 2 |
| Falge, C | 1 |
| Santos, GW | 2 |
| Montastruc, M | 1 |
| Faberes, C | 1 |
| Bilhou-Nabera, C | 1 |
| Gharbi, MJ | 1 |
| Bernard, P | 1 |
| Vezon, G | 1 |
| Broustet, A | 1 |
| Honda, A | 1 |
| Dake, Y | 1 |
| Amemiya, T | 1 |
| Michaeli, J | 1 |
| Fibach, E | 1 |
| Rachmilewitz, EA | 1 |
| Paz, HL | 1 |
| Crilley, P | 4 |
| Topolsky, DL | 1 |
| Coll, WX | 1 |
| Patchefsky, A | 1 |
| Brodsky, I | 2 |
| Biggs, JC | 2 |
| Atkinson, K | 4 |
| Downs, K | 2 |
| Dodds, A | 2 |
| Concannon, AJ | 2 |
| Tutschka, P | 2 |
| Maiolo, A | 1 |
| Kitabayashi, A | 1 |
| Miura, I | 1 |
| Takahashi, M | 2 |
| Chubachi, A | 1 |
| Niitsu, H | 1 |
| Mamiya, S | 1 |
| Miura, AB | 1 |
| Szydlo, R | 2 |
| Ash, RC | 1 |
| Dicke, KA | 1 |
| Gluckman, E | 2 |
| Herzig, RH | 1 |
| Marmont, A | 1 |
| von Bueltzingsloewen, A | 1 |
| Belanger, R | 1 |
| Perreault, C | 1 |
| Bonny, Y | 1 |
| Roy, DC | 1 |
| Lalonde, Y | 1 |
| Boileau, J | 1 |
| Kassis, J | 1 |
| Lavallee, R | 1 |
| Lacombe, M | 1 |
| Uzuka, Y | 2 |
| Saito, Y | 3 |
| About, I | 1 |
| Lauque, D | 1 |
| Levenes, H | 1 |
| Mazerolles, C | 1 |
| Pujazon, MC | 1 |
| Pris, J | 1 |
| Carles, P | 1 |
| Brittig, F | 1 |
| Hargita, M | 1 |
| Marton, E | 1 |
| Kecskés, L | 1 |
| Tehenes, S | 1 |
| Rassam, SM | 1 |
| Katz, F | 1 |
| Chessells, JM | 1 |
| Morgan, G | 1 |
| Stark, RA | 1 |
| Richard, P | 1 |
| Galibert, F | 1 |
| López-Karpovitch, X | 1 |
| Cárdenas, R | 1 |
| Piedras, J | 1 |
| Jehn, U | 1 |
| Pötscher, C | 1 |
| Heinemann, V | 1 |
| Xue, Y | 1 |
| Zhou, XJ | 1 |
| Yu, F | 1 |
| Gu, J | 1 |
| Guo, Y | 1 |
| Xie, X | 1 |
| Lin, B | 1 |
| Cortes, JE | 1 |
| Kantarjian, H | 1 |
| Anseri, H | 1 |
| Johansson, B | 1 |
| Fioretos, T | 1 |
| Billström, R | 1 |
| Mitelman, F | 1 |
| Demirer, T | 1 |
| Lambert, K | 1 |
| Storb, R | 2 |
| Belt, P | 1 |
| Taylor, CA | 1 |
| Ezzone, SA | 1 |
| Scholl, MD | 1 |
| Fisher, J | 1 |
| Young, D | 1 |
| Sahebi, F | 1 |
| Copelan, E | 1 |
| Avalos, B | 2 |
| Klein, J | 1 |
| Territo, M | 1 |
| Izumi, T | 1 |
| Imagawa, S | 1 |
| Hatake, K | 1 |
| Ariyama, T | 1 |
| Inazawa, J | 1 |
| Abe, T | 1 |
| Mandigers, CM | 1 |
| Mensink, EJ | 1 |
| Geurts van Kessel, A | 1 |
| van der Plas, DC | 1 |
| Haanen, C | 1 |
| Hagemeÿer, A | 1 |
| de Witte, T | 1 |
| Richards, SM | 1 |
| Rule, SA | 1 |
| O'Brien, SG | 2 |
| Orchard, K | 1 |
| McDonald, C | 1 |
| Davidson, J | 1 |
| Matthey, F | 1 |
| Reilly, JT | 1 |
| Bardhan, G | 1 |
| Miller, E | 1 |
| Cranfield, T | 1 |
| Apperley, JF | 1 |
| Gudi, R | 1 |
| Elizalde, A | 1 |
| Gogineni, SK | 1 |
| Macera, MJ | 1 |
| Badillo, A | 1 |
| Verma, RS | 1 |
| Zirbes, T | 1 |
| Windecker, R | 1 |
| Fischer, R | 3 |
| Khoroshko, ND | 1 |
| Turkina, AG | 1 |
| Zhuravlev, VS | 1 |
| Sokolova, MA | 1 |
| Mikhaĭlova, IN | 1 |
| Zakharova, AV | 1 |
| Domracheva, EV | 1 |
| Semenova, EA | 1 |
| Carreras, E | 2 |
| Sierra, J | 1 |
| Rovira, M | 2 |
| Urbano-Ispizua, A | 1 |
| Martinez, C | 1 |
| Nomdedeu, B | 1 |
| Cervantes, F | 2 |
| Marín, P | 2 |
| Rozman, C | 1 |
| Montserrat, E | 2 |
| Baldus, SE | 1 |
| Djuren, O | 1 |
| Lienhard, H | 1 |
| Lorenzen, J | 2 |
| Goldman, J | 4 |
| Mross, K | 1 |
| Reifke, J | 1 |
| Bewermeier, P | 1 |
| Kruger, W | 2 |
| Zander, A | 1 |
| Sureda, A | 1 |
| Hernández-Bronchud, M | 1 |
| Armenta, D | 1 |
| Espallargas, C | 1 |
| Paz, A | 1 |
| Rodríguez Martorel, J | 1 |
| Ladines, R | 1 |
| Alvarez, C | 1 |
| Román, J | 1 |
| Andrés, P | 1 |
| Dresbach, S | 1 |
| Manich, B | 1 |
| Lengfelder, E | 1 |
| Leib-Mösch, C | 1 |
| Faber, E | 1 |
| Jarosová, M | 1 |
| Divoký, V | 1 |
| Luhový, M | 1 |
| Komenda, S | 1 |
| Sulovská, I | 1 |
| Hubácek, J | 1 |
| Slezák, P | 1 |
| Papajik, T | 1 |
| Raida, L | 1 |
| Heczko, M | 1 |
| Indrák, K | 1 |
| Urabe, A | 1 |
| Roszkiewicz, A | 1 |
| Roszkiewicz, J | 1 |
| Lange, M | 1 |
| Tukaj, C | 1 |
| Matsuoka, S | 1 |
| Okamoto, S | 1 |
| Ishida, A | 1 |
| Wakui, M | 1 |
| Watanabe, R | 1 |
| Moriki, T | 1 |
| Ikeda, Y | 1 |
| Hirabayashi, N | 2 |
| Carella, AM | 1 |
| Lennard, A | 1 |
| Boogaerts, M | 1 |
| Gorin, NC | 1 |
| Tomas-Martinez, JF | 1 |
| Dabouz-Harrouche, F | 1 |
| Gautier, L | 1 |
| Badri, N | 1 |
| Sharma, S | 1 |
| Kochupillai, V | 1 |
| Pati, HP | 1 |
| Goto, S | 1 |
| Ishii, M | 1 |
| Yuge, M | 1 |
| Mitsuma, A | 1 |
| Noda, N | 1 |
| Boqué, C | 1 |
| Grañena, A | 1 |
| Tefferi, A | 1 |
| Minowa, R | 1 |
| Miyagawa, S | 1 |
| Fukumoto, T | 1 |
| Majima, T | 1 |
| Shimoyama, T | 1 |
| Fujimura, Y | 1 |
| Shirai, T | 1 |
| Omine, M | 1 |
| Kobayashi, T | 1 |
| Naoe, T | 1 |
| Ohshima, T | 1 |
| Hirashima, K | 1 |
| Ohtake, S | 1 |
| Takahashi, I | 1 |
| Morishima, Y | 1 |
| Naito, K | 1 |
| Asou, N | 1 |
| Tanimoto, M | 1 |
| Sakuma, A | 1 |
| Anguita, E | 1 |
| Villegas, A | 1 |
| Díaz-Mediavilla, J | 1 |
| González, FA | 1 |
| del Potro, E | 1 |
| Espinós, D | 1 |
| Muñoz, A | 1 |
| Bureo, E | 1 |
| Ortega, JJ | 1 |
| Richard, C | 1 |
| Olivé, T | 1 |
| Maldonado, MS | 1 |
| Madero, L | 1 |
| Díaz, MA | 1 |
| Manley, R | 1 |
| Cochrane, J | 1 |
| McDonald, M | 1 |
| Rigby, S | 1 |
| Moore, A | 1 |
| Kirk, A | 1 |
| Clarke, S | 1 |
| Crossen, PE | 1 |
| Morris, CM | 1 |
| Patton, WN | 1 |
| Murata, M | 1 |
| Nishida, T | 1 |
| Haneda, M | 1 |
| Kanie, T | 1 |
| Taji, H | 1 |
| Iida, H | 1 |
| Suzuki, R | 1 |
| Hamaguchi, M | 1 |
| Minami, S | 1 |
| Kodera, Y | 1 |
| Guilhot, F | 2 |
| Gibbs, JP | 1 |
| Corneau, B | 1 |
| Murray, G | 1 |
| Stewart, P | 1 |
| Przepiorka, D | 1 |
| Khouri, I | 1 |
| Thall, P | 1 |
| Mehra, R | 1 |
| Lee, MS | 1 |
| Ippoliti, C | 1 |
| Giralt, S | 1 |
| van Besien, K | 1 |
| Andersson, B | 1 |
| Deisseroth, AB | 1 |
| Champlin, R | 1 |
| Silver, RT | 3 |
| Woolf, SH | 1 |
| Anderson, J | 1 |
| Bennett, C | 1 |
| Lichtin, AE | 1 |
| Maloisel, F | 1 |
| Uettwiller, F | 1 |
| Laplace, A | 1 |
| Lioure, B | 1 |
| Herbrecht, R | 1 |
| Mark, M | 1 |
| Dufour, P | 1 |
| Udal'eva, VIu | 2 |
| Bessmel'tsev, SS | 2 |
| Corvò, R | 1 |
| Flowers, ME | 1 |
| Magalhães, SM | 1 |
| Duarte, FB | 1 |
| Ribeiro, SC | 1 |
| Borovik, CL | 1 |
| Lorand-Metze, I | 1 |
| Fiegl, M | 1 |
| Mitterbauer, G | 1 |
| Weltermann, A | 1 |
| Pirc-Danoewinata, H | 1 |
| Jäger, U | 1 |
| Chybicka, A | 2 |
| Bogusławska-Jaworska, J | 2 |
| Kałwak, K | 2 |
| Turkiewicz, D | 2 |
| Armata, J | 2 |
| Balcerska, A | 2 |
| Cwiklińska, M | 2 |
| Hicke-Roberts, A | 1 |
| Kaczmarek-Kanold, M | 2 |
| Kołecki, P | 1 |
| Kowalczyk, J | 2 |
| Krauze, A | 2 |
| Matysiak, M | 2 |
| Płoszyńska, A | 2 |
| Rokicka-Milewska, R | 2 |
| Sońta-Jakimczyk, D | 2 |
| Sikorska-Fic, B | 2 |
| Wiśniewska-Slusarz, H | 2 |
| Wysocki, M | 2 |
| Wachowiak, J | 2 |
| Pecora, AL | 1 |
| Stiff, P | 1 |
| Jennis, A | 1 |
| Goldberg, S | 1 |
| Rosenbluth, R | 1 |
| Price, P | 1 |
| Goltry, KL | 1 |
| Douville, J | 1 |
| Armstrong, RD | 1 |
| Smith, AK | 1 |
| Preti, RA | 1 |
| Ghalaut, PS | 1 |
| Singh, V | 1 |
| Gupta, S | 1 |
| Saikia, TK | 1 |
| Advani, SH | 1 |
| Parikh, PM | 1 |
| Bapna, A | 1 |
| Somjee, S | 1 |
| Mukhopadhyay, A | 1 |
| Gopal, R | 1 |
| Nair, CN | 1 |
| Olavarria, E | 3 |
| Kanfer, E | 2 |
| O'Brien, S | 1 |
| Craddock, C | 2 |
| Apperley, J | 3 |
| Tran, D | 1 |
| Sinclair, RD | 1 |
| Schwarer, AP | 2 |
| Chow, CW | 1 |
| Tsuda, H | 1 |
| Yamasaki, H | 1 |
| Schmitt-Graeff, A | 4 |
| Bundschuh, S | 1 |
| Biermann, T | 1 |
| Roessler, G | 1 |
| Wasmus, M | 1 |
| Zankovich, R | 2 |
| Schaefer, HE | 4 |
| Varadi, G | 1 |
| Cvetanovska, G | 1 |
| Blum, N | 1 |
| Eades, A | 1 |
| Nilsson, C | 1 |
| Timms, A | 1 |
| Matthews, J | 1 |
| Michallet, M | 2 |
| Thiébaut, A | 1 |
| Philip, I | 1 |
| Charrin, C | 1 |
| Vigouroux, C | 1 |
| Thomas, X | 1 |
| Bilger, K | 1 |
| Belhabri, A | 1 |
| Guyotat, D | 1 |
| Corront, B | 1 |
| Salles, B | 1 |
| Dumontet, C | 1 |
| Péaud, PY | 1 |
| Vilque, JP | 1 |
| Devidas, A | 1 |
| Fière, D | 1 |
| Brunstein, CG | 1 |
| Mcglave, PB | 1 |
| Zabelina, T | 1 |
| Renges, H | 1 |
| Stute, N | 1 |
| Kabisch, H | 1 |
| Jaburg, N | 1 |
| Löliger, C | 1 |
| Krüll, A | 1 |
| Kim, I | 1 |
| Park, S | 1 |
| Kim, BK | 1 |
| Chang, HM | 1 |
| Bang, SM | 1 |
| Byun, JH | 1 |
| Kim, DJ | 1 |
| Min, WS | 1 |
| Kim, HJ | 1 |
| Kim, CC | 1 |
| Bennett, M | 1 |
| Grunwald, AJ | 1 |
| Schuler, US | 1 |
| Renner, UD | 1 |
| Kroschinsky, F | 1 |
| Johne, C | 1 |
| Naumann, R | 1 |
| Kiehl, M | 1 |
| Siegert, W | 1 |
| Schetelig, J | 1 |
| Hertenstein, B | 1 |
| Martin, H | 1 |
| Runde, V | 1 |
| Ruutu, T | 2 |
| Sullivan, KM | 1 |
| Chevret, S | 1 |
| Hernández-Boluda, JC | 1 |
| Arellano-Rodrigo, E | 1 |
| Solé, F | 1 |
| Lloveras, E | 1 |
| Espinet, B | 1 |
| Ocejo, A | 1 |
| Petukhov, VI | 1 |
| Strozha, IL | 1 |
| Bondare, DK | 1 |
| Zhu, K | 1 |
| Xu, Y | 1 |
| Wu, D | 1 |
| Xu, X | 1 |
| Huang, L | 1 |
| Liu, B | 1 |
| Hao, C | 1 |
| Liu, Y | 1 |
| Qian, L | 1 |
| Radojkovic, M | 1 |
| Ristic, S | 1 |
| Colovic, M | 1 |
| Todoric, B | 1 |
| Krtolica, K | 1 |
| Saito, T | 1 |
| Kami, M | 1 |
| Kato, K | 1 |
| Shoji, N | 1 |
| Kanai, S | 1 |
| Ohnishi, T | 1 |
| Kawano, Y | 1 |
| Nakai, K | 1 |
| Ogasawara, T | 1 |
| Matsubara, H | 1 |
| Makimoto, A | 1 |
| Tanosaki, R | 1 |
| Tobinai, K | 1 |
| Wakasugi, H | 1 |
| Takaue, Y | 1 |
| Mineishi, S | 1 |
| Zeller, WJ | 1 |
| Bubała, H | 1 |
| Boruczkowski, D | 1 |
| Hicke, A | 1 |
| Kolecki, P | 1 |
| Staszak-Kowalska, R | 1 |
| Tomaszewska, R | 1 |
| Takami, A | 1 |
| Chuhjo, T | 1 |
| Nakao, S | 1 |
| Oetken, C | 1 |
| von Willebrand, M | 1 |
| Autero, M | 1 |
| Andersson, LC | 1 |
| Mustelin, T | 1 |
| Majado, MJ | 1 |
| González García, C | 1 |
| Marín-Blazquez, MD | 1 |
| Morales Lázaro, A | 1 |
| Moreno Moreno, M | 1 |
| Wagner, JE | 1 |
| Broxmeyer, HE | 1 |
| Byrd, RL | 1 |
| Zehnbauer, B | 1 |
| Schmeckpeper, B | 1 |
| Shah, N | 1 |
| Griffin, C | 1 |
| Emanuel, PD | 1 |
| Zuckerman, KS | 1 |
| Cooper, S | 1 |
| Casali, M | 1 |
| Truglio, F | 1 |
| Milone, G | 1 |
| Di Raimondo, F | 1 |
| Parrinello, G | 1 |
| Pasquali, F | 1 |
| Miyake, S | 1 |
| Ohdama, S | 1 |
| Kumagai, T | 1 |
| Ishikawa, M | 2 |
| Umino, T | 1 |
| Takano, S | 1 |
| Akagawa, S | 1 |
| Aoki, N | 1 |
| Matsubara, O | 1 |
| Guseva, SA | 1 |
| Karanas, A | 1 |
| Dear, KB | 1 |
| Weil, M | 1 |
| Brunner, K | 1 |
| Haurani, F | 1 |
| Holland, JF | 2 |
| Glejzer, O | 1 |
| Sedzimirska, M | 1 |
| Tomaszewska-Toporska, B | 1 |
| Tomeczko, J | 1 |
| Kołodziej, J | 1 |
| Pacuszko, T | 1 |
| Was, A | 1 |
| Bocheńska, J | 1 |
| Jaźwiec, B | 1 |
| Klimczak, A | 1 |
| Ready, N | 1 |
| Freeman, NJ | 1 |
| Carvalho, A | 1 |
| Cullis, JO | 1 |
| Hughes, TP | 1 |
| Hows, JM | 1 |
| Franklin, I | 1 |
| Morgenstern, G | 1 |
| Essell, JH | 1 |
| Thompson, JM | 2 |
| Harman, GS | 1 |
| Halvorson, RD | 1 |
| Snyder, MJ | 1 |
| Johnson, RA | 1 |
| Rubinsak, JR | 1 |
| Wickramanayake, PD | 1 |
| Murphy, CP | 1 |
| Harden, EA | 1 |
| Yamauchi, K | 1 |
| Sato, T | 1 |
| Mehta, J | 1 |
| Singhal, S | 1 |
| Mehta, BC | 1 |
| Anger, B | 1 |
| Schmeiser, T | 1 |
| Robertson, J | 1 |
| Sokal, JE | 1 |
| Ganser, A | 1 |
| Carbonell, F | 1 |
| Costa, R | 1 |
| Afonso, E | 1 |
| Benedito, M | 1 |
| Maricato, L | 1 |
| Wehmeier, A | 1 |
| Daum, I | 1 |
| Jamin, H | 1 |
| Schneider, W | 1 |
| Usuka, Y | 1 |
| Fooks, J | 1 |
| Gray, R | 1 |
| Weide, R | 1 |
| Dowding, C | 2 |
| Paulsen, W | 1 |
| Becher, R | 1 |
| Prescher, G | 1 |
| von Wussow, P | 2 |
| Malhotra, OP | 1 |
| Salam, SR | 1 |
| Cao, DC | 1 |
| Tutschka, PJ | 2 |
| Najean, Y | 1 |
| Miclea, M | 1 |
| Tanzer, J | 1 |
| Lessard, M | 1 |
| Sigaux, F | 1 |
| Sagar, TG | 1 |
| Maitreyan, V | 1 |
| Majhi, U | 1 |
| Shanta, V | 1 |
| Klingebiel, T | 1 |
| Creutzig, U | 1 |
| Dopfer, R | 1 |
| Schmidt, H | 1 |
| Ritter, J | 1 |
| Niethammer, D | 1 |
| Urban, C | 1 |
| Schwinger, W | 1 |
| Slavc, I | 1 |
| Schmid, C | 1 |
| Gamillscheg, A | 1 |
| Lackner, H | 1 |
| Hauer, C | 1 |
| Pakisch, B | 1 |
| Hincks, JR | 1 |
| Adlakha, A | 1 |
| Cook, CA | 1 |
| Johnson, CS | 1 |
| Furmanski, P | 1 |
| Gibson, NW | 1 |
| Kobayashi, S | 1 |
| Wakabayashi, Y | 1 |
| Hashimoto, M | 1 |
| Hirose, S | 1 |
| Watanabe, K | 1 |
| Sueishi, K | 1 |
| Nagata, N | 1 |
| Hirose, N | 1 |
| Shigematsu, N | 1 |
| Miake, S | 1 |
| Yoshida, M | 1 |
| Shepherd, P | 1 |
| Harrison, DJ | 1 |
| Jim, RT | 1 |
| Birnie, GD | 1 |
| MacKenzie, ED | 1 |
| Goyns, MH | 1 |
| Pollock, A | 1 |
| Messner, H | 1 |
| Storti, S | 1 |
| Pagano, L | 1 |
| Marra, R | 1 |
| D'Addosio, A | 1 |
| Ricerca, BM | 1 |
| Mancini, R | 1 |
| Bizzi, B | 1 |
| Wiktor-Jedrzejczak, W | 1 |
| Szczylik, C | 1 |
| Matej, H | 1 |
| Pojda, Z | 1 |
| Ratajczak, MZ | 1 |
| Myc, A | 1 |
| Siekierzyński, M | 1 |
| Kansy, J | 1 |
| Kłos, M | 1 |
| Rybicki, Z | 1 |
| Yoshizaki, N | 1 |
| Kohda, K | 2 |
| Nakazawa, O | 1 |
| Ando, M | 1 |
| Miyazaki, S | 1 |
| Muramatsu, H | 1 |
| Terada, S | 1 |
| Kure, T | 1 |
| Niitsu, Y | 1 |
| Papineschi, F | 1 |
| Bonini, R | 1 |
| Pistolisi, D | 1 |
| Spremolla, G | 1 |
| Bowcock, SJ | 2 |
| Brito-Babapulle, F | 1 |
| Marcus, RE | 1 |
| Th'ng, KH | 1 |
| Rassool, F | 1 |
| Guo, AP | 1 |
| Catovsky, D | 1 |
| Polli, EE | 1 |
| Terpstra, W | 1 |
| de Maat, CE | 1 |
| Grever, MR | 1 |
| Sheridan, WP | 1 |
| Boyd, AW | 1 |
| Green, MD | 1 |
| Russell, DM | 1 |
| Thomas, RJ | 1 |
| McGrath, KM | 1 |
| Vaughan, SL | 1 |
| Scarlett, JD | 1 |
| Griffiths, JD | 1 |
| Brodie, GN | 1 |
| Takahira, H | 1 |
| Ideguchi, H | 1 |
| Hirata, J | 1 |
| Nishimura, J | 1 |
| Nawata, H | 1 |
| Shimizu, S | 1 |
| Nagi, K | 1 |
| Matsuo, T | 1 |
| Kuriyama, K | 1 |
| Jinnai, I | 1 |
| Jubashi, T | 1 |
| Nonaka, H | 1 |
| Kohno, T | 1 |
| Tsukasaki, K | 1 |
| Atogami, S | 1 |
| Itoyama, T | 1 |
| Shiga, Y | 1 |
| Yokoyama, A | 1 |
| Ishibashi, T | 1 |
| Shichishima, T | 1 |
| Abe, R | 1 |
| Yui, T | 1 |
| Kimura, H | 1 |
| Matsuda, S | 1 |
| Uchida, T | 1 |
| Kariyone, S | 1 |
| Kato, T | 1 |
| Ohta, Y | 1 |
| Suzumura, Y | 1 |
| Kimoto, H | 1 |
| Kawazoe, Y | 1 |
| Hoffman, R | 1 |
| Graham, L | 1 |
| Newlands, ES | 1 |
| Mick, R | 1 |
| Degnan, TJ | 1 |
| Cavelli, F | 1 |
| Kalra, OP | 1 |
| Prakash, C | 1 |
| Mittal, R | 1 |
| Verma, SC | 1 |
| Mohanty, D | 1 |
| Fülle, HH | 1 |
| Dahmen, E | 1 |
| Hellriegel, KP | 1 |
| Altavilla, V | 1 |
| Cooley, M | 1 |
| Thomas, AE | 1 |
| Patterson, J | 1 |
| Prentice, HG | 1 |
| Brenner, MK | 1 |
| Ganczakowski, M | 1 |
| Hancock, JF | 1 |
| Pattinson, JK | 1 |
| Blacklock, HA | 1 |
| Hopewell, JP | 1 |
| Murray, M | 1 |
| Knüver-Hopf, J | 1 |
| Mohr, H | 1 |
| Pohl, U | 1 |
| Exeriede, G | 1 |
| Wilke, HJ | 1 |
| Misra, RC | 1 |
| Rakshit, MM | 1 |
| Basu, AK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Adipose Derived Stem Cell Therapy in Women With Premature Ovarian Failure[NCT01853501] | Phase 4 | 4 participants (Anticipated) | Interventional | 2012-09-30 | Enrolling by invitation | ||
| Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase III, Multicenter Trial With P[NCT03117816] | Phase 3 | 214 participants (Actual) | Interventional | 2017-05-04 | Completed | ||
| Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia[NCT00390897] | Phase 4 | 360 participants | Interventional | 2003-07-31 | Completed | ||
| Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy[NCT00755911] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Phase II Study of Pevonedistat (MLN4924, TAK924) and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission Acute Myelogenous Leukemia[NCT03709576] | Phase 2 | 3 participants (Actual) | Interventional | 2018-07-18 | Terminated (stopped due to Funding pulled) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary objective of this study is to determine whether the placement of Tissue Repair Cells (TRCs) at the time of tooth extraction can safely and effectively promote bone regeneration in alveolar bone defects created by tooth extraction.~Safety was assessed through adverse event reporting~Bone regeneration was assessed through measures of bone mineral density and bone volume fraction of biopsied regenerated bone tissue. Bone regeneration was also measured through radiographic analysis of relative bone height gain (% of the bone height regenerated relative to the height before tooth extraction)" (NCT00755911)
Timeframe: 12 months after tooth extraction
| Intervention | % bone height (Mean) |
|---|---|
| Tissue Repair Cells (TRC) | 79 |
| Control | 63 |
The secondary objective is to determine if Tissue Repair Cell therapy regenerates bone enabling the installation and stability of dental implant fixtures (NCT00755911)
Timeframe: 12 months after tooth extraction
| Intervention | participants (Number) |
|---|---|
| Tissue Repair Cells (TRC) | 12 |
| Control | 12 |
42 reviews available for busulfan and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
[Treatment of chronic myeloid leukemia in chronic phase].
Topics: Allografts; Benzamides; Busulfan; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib | 2014 |
Hematopoietic cell transplantation in chronic myeloid leukemia in the age of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Busulfan; Combined Modality Therapy; Cost-Benefit Analysis; Fetal Blood; Hema | 2015 |
[Current therapy of chronic myeloid leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Enzyme | 2003 |
CYTOGENETIC STUDIES IN CHRONIC MYELOID LEUKEMIA.
Topics: Antineoplastic Agents; Blood Cells; Bone Marrow Examination; Busulfan; Chromosome Aberrations; Cytog | 1963 |
PORPHYRIA CUTANEA TARDA ASSOCIATED WITH CHRONIC GRANULOCYTIC LEUKEMIA TREATED WITH BUSULFAN (MYLERAN).
Topics: Busulfan; Feces; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Pigm | 1964 |
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, | 2004 |
Chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Busulfan; Humans; Hydroxyurea; Imatinib Mesylate; Interferons; Le | 2004 |
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Combined Modalit | 1994 |
[The assessment of therapeutic success in chronic myeloid leukemia].
Topics: Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Humans; Hydroxyurea; Interferon-al | 1995 |
New perspectives with interferon alpha. The German CML study group experience.
Topics: Busulfan; Clinical Trials as Topic; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Ch | 1994 |
Approaches to the treatment of chronic myeloid leukemia.
Topics: Bone Marrow Transplantation; Busulfan; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic | 1994 |
Update on therapy for chronic myelogenous leukemia.
Topics: Bone Marrow Transplantation; Busulfan; Histocompatibility; Humans; Hydroxyurea; Interferon-alpha; Le | 1994 |
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Cytarabine; Humans; Hydroxyurea; Inter | 1994 |
Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
Topics: Bone Marrow Transplantation; Busulfan; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Interferon-alp | 1994 |
Management of chronic myeloid leukaemia.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Blast Crisis; Bone Marrow Transplantation; Busulfan; Ch | 1994 |
Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia--a review.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Canada; Child; Clinic | 1993 |
[Cataracts in a patient treated with busulfan (Mablin powder) for eight years].
Topics: Busulfan; Cataract; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle A | 1993 |
[Alveolar opacities and busulfan pneumonia].
Topics: Aged; Biopsy; Blood Gas Analysis; Busulfan; Diagnosis, Differential; Humans; Leukemia, Myelogenous, | 1993 |
The management of elderly patients with myeloproliferative disorders.
Topics: Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Chronic Disease; Humans; Hydroxyure | 1993 |
Chronic myelogenous leukemia: a review.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Ph | 1996 |
Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Chromosomes, Human, Pair 8; Comb | 1996 |
Characterization of a complex translocation [t(4;9;22)(p16;q34;q11)] in chronic myelogenous leukemia by fluorescence in situ hybridization technique.
Topics: Allopurinol; Antineoplastic Agents; Bone Marrow; Busulfan; Chromosome Banding; Chromosome Mapping; C | 1996 |
Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 1996 |
ABC of clinical haematology. Chronic myeloid leukaemia.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positiv | 1997 |
The management of chronic myeloid leukaemia--a case history.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Transplantation; Busulfan; | 1997 |
[Recent progress in therapy for chronic myelogenous leukemia].
Topics: Age Factors; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Cytarabine; Humans; Hydro | 1997 |
Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Humans; | 1997 |
[Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 1998 |
Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission: CML or sensitivity of detection?
Topics: Adult; Biomarkers, Tumor; Blotting, Southern; Busulfan; Female; Fusion Proteins, bcr-abl; Humans; Le | 1998 |
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Moda | 1999 |
[Total body irradiation in hematology: clinical indications and prospects].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1999 |
Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group.
Topics: Antineoplastic Agents; Busulfan; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 2000 |
The biology and treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Cy | 2001 |
[Chronic myeloid leukemia: current pathogenetic aspects and new therapeutic approaches (a foreign literature review)].
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Humans; Hydr | 2001 |
[Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transpl | 1992 |
Treatment choices in chronic myelogenous leukemia.
Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Humans; Hydroxyurea; Interferon-alpha; Leukemia, | 1992 |
[Busulfan lung exacerbated during steroid therapy: a review of Japanese literature].
Topics: Busulfan; Dexamethasone; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Male; Middl | 1990 |
Treatment of chronic myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Busulfan; Dose-Response Relationship, | 1987 |
[Chronic myelocytic leukemia].
Topics: Busulfan; Combined Modality Therapy; Humans; Hydroxyurea; Interferons; Leukemia, Myelogenous, Chroni | 1989 |
[A case of chronic myelogenous leukemia complicated with nephrotic syndrome].
Topics: Aged; Aged, 80 and over; Busulfan; Drug Therapy, Combination; Female; Glomerulonephritis, Membranopr | 1989 |
Therapeutic options in chronic myeloid leukaemia.
Topics: Blast Crisis; Bone Marrow Transplantation; Busulfan; Humans; Hydroxyurea; Leukemia, Myelogenous, Chr | 1989 |
High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamid | 1989 |
53 trials available for busulfan and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Allografts; Busulfan; Cyclopho | 2015 |
Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 2009 |
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2002 |
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Fo | 2003 |
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Bone Mar | 2003 |
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow Transplantation; Busulfan; Child; Dose-Respo | 2004 |
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplas | 2005 |
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft | 2008 |
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Combined Modalit | 1994 |
The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Bone Marrow; Busulfan; Female; Humans; Interfero | 1995 |
Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
Topics: Adult; Antigens, CD; Antigens, CD34; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclos | 1995 |
Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial.
Topics: Antineoplastic Agents, Alkylating; Blast Crisis; Busulfan; Female; Humans; Leukemia, Myelogenous, Ch | 1995 |
A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.
Topics: Adult; Blood Cell Count; Bone Marrow; Busulfan; Chronic Disease; Female; Humans; Interferon-alpha; L | 1995 |
Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Disease-Free Surv | 1995 |
Estimation of chronic phase duration in Ph-positive chronic myelocytic leukemia treated with busulfan: statistical analysis on Japanese patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Child; Female; Humans; Japan; Leukemia, Myelog | 1994 |
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blast Crisis; Busulfan; Cross-Over Studies; Drug Resista | 1994 |
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
Topics: Adolescent; Adult; Bilirubin; Bone Marrow Transplantation; Busulfan; Child; Creatinine; Cyclophospha | 1994 |
Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.
Topics: Busulfan; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, | 1994 |
Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combin | 1993 |
Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
Topics: Bone Marrow Transplantation; Busulfan; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Interferon-alp | 1994 |
Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclopho | 1994 |
Chronic myelogenous leukemia: progress in chemotherapy and evaluation of prognostic score 1. The German CML Study Group.
Topics: Busulfan; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; P | 1993 |
The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Topics: Adult; Busulfan; Female; Germany; Germany, West; Humans; Hydroxyurea; Immunologic Factors; Interfero | 1993 |
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
Topics: Blast Crisis; Busulfan; Drug Resistance; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic | 1993 |
Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase.
Topics: Actuarial Analysis; Bone Marrow Transplantation; Busulfan; Follow-Up Studies; Humans; Hydroxyurea; L | 1993 |
Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Antineoplastic Combined | 1995 |
Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Germany; Humans; Hydroxyurea; Immu | 1996 |
Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1996 |
Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Ch | 1996 |
Progress with interferon in CML--results of the MRC UK CML III study.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelo | 1996 |
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Humans; Hydroxy | 1997 |
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group.
Topics: Antineoplastic Agents; Busulfan; Cell Line; Genome, Human; Germany; Humans; Hydroxyurea; Leukemia, M | 1997 |
[Interferon-alpha in the treatment of patients with chronic myeloid leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Humans; Hydroxyurea; Interf | 1997 |
A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group.
Topics: Adult; Aged; Busulfan; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Interferon-a | 1998 |
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Blast Crisis; Bone Marrow Transplantation; Busulfan; Cyclo | 1999 |
Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Moda | 1999 |
[Low doses of alpha-interferon preparations in the treatment of patients with chronic myeloleukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2000 |
A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation.
Topics: Acute Disease; Adult; Busulfan; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cyc | 2000 |
Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-alpha.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Granulocyte Colony-Stimulat | 2000 |
Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disea | 2001 |
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
Topics: Adolescent; Adult; Alopecia; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cycloph | 2001 |
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Combined Modality Therapy; Graf | 2002 |
[Characteristics of the effect of myelosan on the immune status of patients with chronic myeloid leukemia].
Topics: Adjuvants, Immunologic; B-Lymphocytes; Busulfan; Humans; Immunity; Immunoglobulins; Immunologic Defi | 1992 |
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Busulfan; Cytarabine; Female; Follow-U | 1992 |
Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1992 |
Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide.
Topics: Actuarial Analysis; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Follow-U | 1992 |
Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group.
Topics: Bone Marrow Transplantation; Busulfan; Female; Germany; Humans; Hydroxyurea; Interferon-alpha; Leuke | 1992 |
[Evaluation of 196 patients with chronic myeloid leukemia based on a standard prognosis model].
Topics: Biomarkers, Tumor; Blast Crisis; Busulfan; Clinical Trials as Topic; Female; Follow-Up Studies; Huma | 1990 |
Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine.
Topics: Alkaline Phosphatase; Ascites; Bilirubin; Busulfan; Chemical and Drug Induced Liver Injury; Esophage | 1991 |
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)].
Topics: Busulfan; Female; Follow-Up Studies; Humans; Hydroxyurea; Interferon Type I; Leukemia, Myelogenous, | 1991 |
Bone marrow transplantation in comparison with conventional therapy in children with adult type chronic myelogenous leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1990 |
[Ranimustine].
Topics: Antineoplastic Agents; Busulfan; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Po | 1990 |
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis-chloronitrosurea during the course of busulfan-maintained remission.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Busulfan; Clinical | 1988 |
261 other studies available for busulfan and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
A novel drug interaction between busulfan and blinatumomab.
Topics: Adult; Antibodies, Bispecific; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; D | 2019 |
Melatonin protects spermatogonia from the stress of chemotherapy and oxidation via eliminating reactive oxidative species.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Busulfan; Cells, Cultured; Drug | 2019 |
Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Bone Marrow Cells; Busulfan; Drug Resistance, Neoplasm; Humans; Hydroxyurea; | 2014 |
In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Cell Proliferation; Cyclophosp | 2014 |
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Gr | 2016 |
Successful pregnancy following busulfan and cyclophosphamide conditioning and allogeneic bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Humans; Leukemia, Myelogenou | 2008 |
Chronic myeloid leukemia: an historical perspective.
Topics: Antineoplastic Agents; Busulfan; History, 19th Century; History, 20th Century; Humans; Leukemia, Mye | 2008 |
A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting.
Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Don | 2009 |
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY.
Topics: Adult; Busulfan; Cyclophosphamide; Cytomegalovirus; Etoposide; Hematopoietic Stem Cell Transplantati | 2011 |
Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Dose-Response | 2010 |
Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Benzamides; Busulfan; Child; Cyclophosphamide; Female; Fusion Proteins, bcr-abl; | 2011 |
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cohort Studies; | 2011 |
Risks and benefits of ovarian shielding in female patients undergoing TBI: a decision analysis.
Topics: Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, B | 2011 |
Effect of splenectomy on pancytopenia after a peripheral blood stem cell transplantation.
Topics: Adult; Busulfan; Cyclophosphamide; Dexamethasone; Female; Graft Survival; Graft vs Host Disease; Hem | 2011 |
Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Topics: Adult; Benzamides; Blast Crisis; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine | 2011 |
Leukemia with pigmentation.
Topics: Busulfan; Humans; Hyperpigmentation; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pig | 1965 |
Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.
Topics: Adolescent; Age Factors; Anemia, Aplastic; Area Under Curve; Busulfan; Cyclophosphamide; Dose Fracti | 2011 |
Dunnett-type inference in the frailty Cox model with covariates.
Topics: Antineoplastic Agents; Busulfan; Computer Simulation; Data Interpretation, Statistical; Female; Huma | 2012 |
Primary ovarian dysfunction after hematopoietic stem cell transplantation during childhood: busulfan-based conditioning is a major concern.
Topics: Adolescent; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myel | 2011 |
Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting.
Topics: Administration, Oral; Anticonvulsants; Antineoplastic Agents, Alkylating; Busulfan; Dose-Response Re | 2012 |
[Chronic myeloid leukemia in hemophilia B].
Topics: Adult; Blood Coagulation Factors; Busulfan; Fatal Outcome; Hemophilia B; Humans; Immunosuppressive A | 2002 |
Parenteral busulfan: is therapeutic monitoring still warranted?
Topics: Bone Marrow Transplantation; Busulfan; Drug Monitoring; Hepatic Veno-Occlusive Disease; Humans; Infu | 2002 |
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2003 |
HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; C | 2003 |
Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi.
Topics: Adolescent; Adult; Age Distribution; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combine | 2002 |
Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration.
Topics: Adult; Antineoplastic Agents; Benzamides; Busulfan; Cardiomegaly; Cyclophosphamide; Echocardiography | 2003 |
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2003 |
Myleran in chronic myeloid leukaemia; chemical constitution and biological action.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Le | 1953 |
Myleran in chronic myeloid leukaemia; results of treatment.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1953 |
Myleran in chronic myeloid leukaemia.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1955 |
The use of myleran in the treatment of chronic myelocytic leukemia.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1955 |
Treatment of chronic granulocytic leukemia with myleran.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1956 |
Myleran in treatment of chronic myeloid leukaemia.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1956 |
Myleran in the treatment of chronic granulocytic leukemia.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1956 |
Myleran therapy in malignant neoplastic disease; use of 1,4-dimethanesulfonyloxbutane with emphasis on chronic granulocytic leukemia.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms | 1956 |
Treatment of chronic granulocytic leukemia with 1, 4-dimethanesulfonyloxybutane (myleran).
Topics: Anemia; Anemia, Myelophthisic; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1956 |
Chemotherapy of leukaemia. I. Myleran in the treatment of chronic myeloid leukaemia.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1956 |
[Treatment of chronic myeloid leukemia with 1, 4-butanediol dimethylsulfonyl ester (busulfan)].
Topics: Busulfan; Butylene Glycols; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk | 1956 |
[Treatment of chronic myeloid leukemia with 1, 4-butanediol dimethylsulfonyl ester (busulfan)].
Topics: Busulfan; Butylene Glycols; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk | 1956 |
[Treatment of chronic myeloid leukemia with 1, 4-butanediol dimethylsulfonyl ester (busulfan)].
Topics: Busulfan; Butylene Glycols; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk | 1956 |
[Treatment of chronic myeloid leukemia with 1, 4-butanediol dimethylsulfonyl ester (busulfan)].
Topics: Busulfan; Butylene Glycols; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk | 1956 |
[Continuous therapy of chronic myeloid leukemia with myleran (sulfabutin)].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Speech | 1957 |
Myleran treatment in chronic granulocytic leukaemia.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1957 |
The treatment of chronic myeloid leukaemia with myleran.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1957 |
[Treatment of chronic myeloid leukemia with myleran].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1957 |
Case report chronic myelogenous leukemia; an eight year experience.
Topics: Blood Transfusion; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leu | 1957 |
[Myleran in chronic myeloid leukemia; importance of systematic maintenance therapy].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1956 |
[Colcemid and myleran in the treatment of chronic myelosis].
Topics: Busulfan; Colchicine; Demecolcine; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuke | 1957 |
Treatment of chronic granulocytic leukemia with myleran.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1957 |
[1-4-Dimethanesulfoxybutane therapy of chronic leukemic myeloses].
Topics: Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1957 |
[Treatment of chronic myelocytic leukemia with myleran].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1957 |
Medullary aplasia in chronic myeloid leukaemia during busulphan therapy.
Topics: Anemia; Anemia, Aplastic; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 1957 |
[Early result of myleran therapy of chronic myeloid leukemias].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1957 |
[Treatment of chronic myeloid leukemia with myleran].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1958 |
[Aplastic anemia following myleran treatment of chronic myeloid leukemia].
Topics: Anemia; Anemia, Aplastic; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 1958 |
[Data on an unusual acute transformation in a case of chronic myeloid leukemia following dimethylsulfonoxy-butane therapy].
Topics: Blood; Busulfan; Butanes; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukem | 1958 |
[Myleran therapy of chronic myeloid leukemia].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1958 |
[Treatment of chronic myeloid leukemia by means of a new chemical antiblastic agent, 1-4-dimethylsulfonoxy-butane].
Topics: Busulfan; Butanes; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Mye | 1958 |
Myleran and triethylene melamine in the treatment of chronic granulocytic leukemia.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Triethylene | 1958 |
Effect of my-leran and 6-mercaptopurine (6-MP) on the serum level of vitamin B12 in chronic myelocytic leukemia.
Topics: Busulfan; Hematinics; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; | 1959 |
[Bone marrow aplasia consecutive to myleran therapy of chronic myeloid leukemia].
Topics: Anemia, Aplastic; Bone Marrow; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1959 |
[Changes in the lipoid and carbohydrate metabolism in patients with chronic myelosis under the influence of ACTH and myelosan therapy].
Topics: Adrenocorticotropic Hormone; Busulfan; Carbohydrate Metabolism; Leukemia, Myelogenous, Chronic, BCR- | 1961 |
[Chemotherapy of leukemic myelosis with 1,4-dimethylsulfonoxybutane (myeleukon)].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1960 |
Busulfan in the treatment of chronic myelocytic leukemia. The effect of long term intermittent therapy.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1961 |
[Total bone marrow aplasia caused by uncontrolled treatment with dimethanesulfonoxybutane in a case of chronic myelocytic leukemia].
Topics: Bone Marrow; Bone Marrow Diseases; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-A | 1960 |
[Experiences with sulfabutin in the therapy of chronic myelosis].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1960 |
Leukocytic alkaline phosphatase in busulfan-induced remissions of chronic granulocytic leukemia.
Topics: Alkaline Phosphatase; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 1961 |
[Chronic myeloid leukemia during pregnancy successfully treated with busulfan].
Topics: Busulfan; Female; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Pre | 1959 |
[Treatment of chronic myeloid leukemia with myleran].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1960 |
[Immediate results of treatment of chronic myelosis with myleran].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1959 |
Combined x-ray and myleran treatment of chronic myelosis.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; X-Rays | 1959 |
Myleran in the treatment of chronic myelogenous leukemia.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1959 |
[Bone marrow hematopoiesis in patients with chronic myelosis before and after treatment with myleran].
Topics: Bone Marrow; Busulfan; Hematopoiesis; Hematopoietic System; Leukemia; Leukemia, Myelogenous, Chronic | 1959 |
[Giant nuclei after myleran therapy and spleen irradiation in chronic myeloid leukemia].
Topics: Busulfan; Cell Nucleus; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia | 1960 |
[Bone marrow aplasia in therapy of chronic myelosis with myleran].
Topics: Anemia, Aplastic; Bone Marrow; Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 1961 |
Busulphan in the treatment of chronic granulocytic leukaemia.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1961 |
[Effect of mannitolmyleran (1,6 dimethanesulfonoxy-D-mannitol) in chronic myeloid leukemia].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mannitol | 1961 |
[Long-term chemotherapy of chronic myeloid leukemia with Myleran and C69].
Topics: Antineoplastic Agents; Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemi | 1962 |
[Changes in antitoxic and prothrombin- and bilirubin-producing functions of the liver in patients with chronic myelosis treated with myelosan (Myleran)].
Topics: Bilirubin; Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; | 1962 |
[Treatment of chronic myeloid leukemia with Mannit-busulfan].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mannitol | 1961 |
[Treatment of chronic myelosis with Myleran (myeleukon) with special reference to alkaline leukocyte phosphatase activity].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukocytes; | 1961 |
Evaluation of the comparative effectiveness of Myleran and 6-MP in the management of patients with chronic myelocytic leukemia.
Topics: Busulfan; Disease Management; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, | 1962 |
[Treatment with myelosan of patients with chronic myeloid leukemia].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1962 |
Chronic myeloid leukaemia: cytogenetic studies before and after splenic irradiation.
Topics: Busulfan; Chromosomes; Cytogenetic Analysis; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-A | 1962 |
[Aplasia of the bone marrow in patients with chronic myelocytic leukemia treated with myelosan].
Topics: Anemia; Anemia, Aplastic; Bone Marrow; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, B | 1962 |
Chronic granulocytic leukemia and cancer. Report of a case.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mercaptopurine; Neoplasms; Rad | 1963 |
THE EFFECT OF TREATMENT IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA. BIOCHEMICAL STUDIES.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Busulfan; Chromosome Aberrations; Colchicine; Humans; H | 1963 |
[REMOTE RESULTS OF MYELOSAN THERAPY OF CHRONIC MYELOID LEUKEMIA].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Neoplasms | 1963 |
[REPEATED THERAPY OF CHRONIC MYELOSES BY COMBINED APPLICATION OF MYLERAN AND IRRADIATION OF THE SPLEEN].
Topics: Busulfan; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Ne | 1963 |
[THERAPEUTIC SYNERGISM AS A PROBABLE EXPLANATION FOR THE COMBINED EFFECT OF X-RAY IRRADIATION AND MYLERAN IN CHRONIC MYELOSES].
Topics: Busulfan; Hemoglobinometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Coun | 1964 |
STUDIES OF THE PHILADELPHIA CHROMOSOME IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Bone Marrow Examination; Busulfan; Cell Division; Chrom | 1964 |
MULTIVARIATE COMPARISON OF RESULTS OF TREATMENT IN CHRONIC LYMPHOCYTIC AND CHRONIC GRANULOCYTIC LEUKEMIA.
Topics: Antineoplastic Agents; Blood Platelets; Busulfan; Chlorambucil; Factor Analysis, Statistical; Hemogl | 1964 |
CHRONIC MYELOID LEUKEMIA WITH PRIAPISM IN EIGHT-YEAR-OLD CHILD.
Topics: Blood Chemical Analysis; Blood Platelets; Busulfan; Child; Chromosome Aberrations; Erythrocyte Count | 1964 |
BLASTIC CRISIS IN CHRONIC GRANULOCYTIC LEUKAEMIA. CYTOCHEMICAL, CYTOGENETIC, AND AUTORADIOGRAPHIC STUDIES IN FOUR CASES.
Topics: Adolescent; Alkaline Phosphatase; Autoradiography; Bone Marrow Examination; Busulfan; Chromosome Abe | 1964 |
COMPARISON OF CYCLOPHOSPHAMIDE (CYTOXAN AND URACIL MUSTARD (U-8344) IN CHRONIC GRANULOCYTIC LEUKEMIA.
Topics: Adolescent; Busulfan; Cyclophosphamide; Geriatrics; Leukemia; Leukemia, Lymphoid; Leukemia, Myelogen | 1964 |
DEFICIENCY OF THE HYDRAZINE SENSITIVE COMPONENT OF COMPLEMENT IN A PATIENT WITH CHRONIC MYELOGENOUS LEUKEMIA.
Topics: Animals; Blood Protein Electrophoresis; Busulfan; Complement System Proteins; Erythrocytes; Guinea P | 1963 |
[COMBINED TREATMENT OF CHRONIC MYELOCYTIC LEUKEMIA].
Topics: Blood Transfusion; Busulfan; Cortisone; Erythrocyte Count; Hemoglobinometry; Humans; Leukemia; Leuke | 1963 |
SKIN LESIONS IN CHRONIC MYELOID LEUKAEMIA.
Topics: Blood Transfusion; Busulfan; Dermatology; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL | 1964 |
SUBMETACENTRIC CHROMOSOME IN CHRONIC MYELOCYTIC LEUKEMIA.
Topics: Busulfan; Chromosomes; Drug Therapy; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leu | 1964 |
A CYTOGENETIC STUDY ON THE THERAPEUTIC EFFECT OF MYLERAN IN A CASE OF CHRONIC MYELOID LEUKAEMIA.
Topics: Busulfan; Chromosomes; Cytogenetic Analysis; Drug Therapy; Humans; Leukemia; Leukemia, Myelogenous, | 1963 |
[STUDY OF THE CHROMOSOMES IN CHRONIC GRANULOCYTIC LEUKEMIA].
Topics: Busulfan; Chromosomes; Genetics, Medical; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1964 |
SEVERAL CELL-LINES WITH ABNORMAL KARYOTYPES IN A PATIENT WITH CHRONIC MYELOGENOUS LEUKAEMIA.
Topics: Abnormal Karyotype; Blood Cell Count; Bone Marrow Examination; Busulfan; Chromosome Aberrations; Chr | 1964 |
HAEMOPERICARDIUM IN CHRONIC MYELOID LEUKAEMIA.
Topics: Adolescent; Busulfan; Drug Therapy; Electrocardiography; Hemorrhage; Humans; India; Joint Diseases; | 1964 |
DIHYDROXYBUSULFAN (NSC-39069) IN CHRONIC MYELOCYTIC LEUKEMIA AND MISCELLANEOUS MALIGNANT NEOPLASMS.
Topics: Busulfan; Drug Therapy; Geriatrics; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk | 1964 |
PRESENCE OF TWO PH-1 CHROMOSOMES IN CELLS FROM A PATIENT WITH CHRONIC GRANULOCYTIC LEUKAEMIA.
Topics: Bone Marrow Examination; Busulfan; Chromosome Aberrations; Drug Therapy; Humans; Leukemia; Leukemia, | 1965 |
CHRONIC MYELOID LEUKAEMIA IN CHILDREN.
Topics: Adolescent; Busulfan; Child; Humans; India; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 1965 |
SOME BIOCHEMICAL ASPECTS OF LEUKAEMIAS: THE APPEARANCE OF A SOLUBLE DISULPHIDE IN THE BLOOD IN CHRONIC GRANULOCYTIC LEUKAEMIA.
Topics: Biochemical Phenomena; Biochemistry; Blood Chemical Analysis; Busulfan; Disulfides; Erythrocytes; Gl | 1964 |
LEUKOKINETIC STUDIES. X. BLOOD GRANULOCYTE KINETICS IN CHRONIC MYELOCYTIC LEUKEMIA.
Topics: Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Division; Colchicine; Granulocytes; H | 1965 |
STEROID HORMONE METABOLISM IN CHRONIC MYELOGENOUS LEUKEMIA.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Androgens; Androsterone; Busulfan; Cyclophosphamide; Dehyd | 1965 |
GASTRIC PLASMACYTOMA (OR LYMPHOMA) FOLLOWED BY CHRONIC MYELOID LEUKAEMIA: A RARE LYMPHO-MYELO-PROLIFERATIVE DISORDER.
Topics: Anemia; Anemia, Macrocytic; Blood Cell Count; Busulfan; Drug Therapy; Gastrectomy; Humans; Leukemia; | 1965 |
[BIOPTIC STUDIES ON THE PROBLEM OF THERAPY-INDUCED BONE MARROW FIBROSES IN CHRONIC MYELOID LEUKEMIA].
Topics: Busulfan; Drug Therapy; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia | 1965 |
[SUPPORTIVE THERAPY IN CHRONIC MYELOCYTIC LEUKEMIA].
Topics: Busulfan; Drug Therapy; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloi | 1964 |
[MELANODERMA IN THE COURSE OF TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH MYLERAN].
Topics: Busulfan; Drug Therapy; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia | 1965 |
[Myleran in the treatment of chronic myelocytic leukemia].
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1954 |
[The treatment of patients with chronic myeloid leukemia with myleran in polyclinical conditions].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1960 |
[Pregnancy in a woman with chronic myelocytic leukemia treated with myleran].
Topics: Busulfan; Female; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Pre | 1960 |
Acute myeloblastic transformation after busulfan treatment of chronic myelocytic leukemia.
Topics: Busulfan; Granulocyte Precursor Cells; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Pos | 1959 |
[On cytopenia in a female patient with chronic myeloid leukemia following myelosan therapy].
Topics: Anemia; Anemia, Aplastic; Busulfan; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-AB | 1962 |
C-myc expression in cell lines derived from chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Busulfan; Cell Division; Cell Line, Tumor; Gene Expres | 2004 |
Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia.
Topics: Adolescent; Adult; Body Mass Index; Busulfan; Cyclophosphamide; Female; Genotype; Graft vs Host Dise | 2004 |
[Comparative efficiency of conventional myelosuppressive chemotherapy and therapy including interferon alpha in patients with chronic myeloid leukemia].
Topics: Adult; Aged; Busulfan; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Interfer | 2004 |
Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and ce
Topics: Adult; Bayes Theorem; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Therapy, Combina | 2004 |
Long-term cytogenetic remission with ubenimex monotherapy in a case of chronic myeloid leukemia.
Topics: Aged; Bone Marrow Cells; Busulfan; Humans; Immunologic Factors; Leucine; Leukemia, Myelogenous, Chro | 2004 |
Effect of interferon-alpha on chromosome abnormalities in treated chronic myelogenous leukemia patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busu | 2004 |
Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Diseases; Busulfan; Fatal Outcome; Female; Humans; Im | 2005 |
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Th | 2006 |
[Comparison of the long term results between two conditioning regimens MCC and BuCy in chronic myelocytic leukemia after allogeneic stem cell transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Drug Administrati | 2006 |
Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; C | 2006 |
[Modulating effect of antileukemia drugs on the cellular susceptibility in chronic myeloid leukemia to cytotoxic lymphocytes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Humans; Hydroxyurea; K562 Cell | 2006 |
Alloimmune hepatitis following peripheral stem cell transplantation.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Busulfan; Cyclophosphamide; Female; Graft vs Host Dis | 2007 |
Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Antilymphocyte Serum; Busulfan; Child; Disease-Free Survival; Female | 2007 |
Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Busulfan; Fatal Outcome; Humans; Imatinib Me | 2008 |
Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia.
Topics: Adult; Blood Transfusion; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Colony-Forming U | 1981 |
Busulphan and melphalan prior to autologous transplantation for myeloid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1995 |
Recombinant human erythropoietin at high doses stimulates thrombopoiesis: treatment for protracted severe myelosuppression complicating interferon-alpha and busulfan therapy for chronic myelogenous leukaemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Dose-Response Relationship, Drug; Erythrocyte Tr | 1995 |
Acute myeloblastic leukaemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukaemia with Philadelphia chromosome.
Topics: Aged; Busulfan; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 8; Humans; Interferon-alpha; K | 1995 |
Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Eosinop | 1994 |
Pregnancy in a patient receiving busulphan for chronic myeloid leukaemia.
Topics: Adult; Busulfan; Female; Humans; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 1994 |
Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia.
Topics: Adult; Aged; Bone Marrow Diseases; Busulfan; Combined Modality Therapy; Female; Humans; Hydroxyurea; | 1994 |
Retinal microvascular changes following bone marrow transplantation: the role of cyclosporine.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclosporine; F | 1994 |
[A comparative analysis of the effect of alpha 2-interferon (reaferon) therapy on the morphofunctional state of the bone marrow in patients with chronic myeloleukemia].
Topics: Adolescent; Adult; Biopsy, Needle; Bone Marrow; Bone Marrow Examination; Busulfan; Drug Evaluation; | 1993 |
Molecular analysis of an asymptomatic Ph-positive CML patient with 27 years of prolonged remission.
Topics: Aged; Busulfan; Chromosome Mapping; DNA, Neoplasm; Female; Gene Rearrangement; Humans; Leukemia, Mye | 1994 |
New strategies for the treatment of chronic myeloid leukemia.
Topics: Busulfan; Combined Modality Therapy; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Trans | 1994 |
Cataract after prolonged busulphan therapy.
Topics: Adult; Busulfan; Cataract; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Time Fact | 1993 |
Hepatocellular carcinoma with splenic metastasis developing after 16 years of chemotherapy for chronic myelogenous leukemia: a case report.
Topics: Busulfan; Carcinoma, Hepatocellular; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver | 1994 |
Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Topics: Adolescent; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocol | 1994 |
[Chronic myeloid leukemia (CML) and solid neoplasms. Description of 3 cases].
Topics: Aged; Breast Neoplasms; Busulfan; Carcinoma, Hepatocellular; Combined Modality Therapy; Fatal Outcom | 1994 |
The efficacy of chemotherapy and splenic irradiation in the management of chronic myelogenous leukaemia at Ibadan, Nigeria.
Topics: Busulfan; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Developing Countries; Female; | 1993 |
[Clinical study of chronic myelogenous leukemia].
Topics: Blast Crisis; Bone Marrow Transplantation; Busulfan; Granulocytes; Humans; Hydroxyurea; Interferon-a | 1993 |
Renal cancer after busulphan treatment for chronic myeloid leukemia. A case report.
Topics: Busulfan; Humans; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle A | 1993 |
Autologous blood stem cell transplantation followed by recombinant alpha interferon as treatment for patients with high-risk chronic myelogenous leukemia. A report of 32 cases.
Topics: Adult; Blast Crisis; Blood Component Transfusion; Blood Transfusion, Autologous; Bone Marrow Purging | 1993 |
Induction of differentiation of myeloid leukemic cells by busulphan: in vivo and in vitro observations.
Topics: Aged; Bone Marrow; Busulfan; Cell Differentiation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1993 |
Bronchiolitis obliterans after bone marrow transplantation: the effect of preconditioning.
Topics: Adult; Bone Marrow Transplantation; Bronchiolitis Obliterans; Busulfan; Cyclophosphamide; Female; Gr | 1993 |
Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Child; Combined Mod | 1993 |
Renal cancer after busulphan treatment for chronic myeloid leukemia: therapeutic implications.
Topics: Busulfan; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1993 |
[Partial and complete disappearance of Ph1 chromosome in two patients with chronic myelogenous leukemia after conventional chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Leukemia, Mye | 1993 |
Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
Topics: Adult; Busulfan; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Female; | 1993 |
[Bestatin therapy of chronic myelogenous leukemia].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; | 1993 |
["Busulfan lung" simulating tumor].
Topics: Biopsy; Bronchoalveolar Lavage Fluid; Busulfan; Diagnosis, Differential; Humans; Leukemia, Myelogeno | 1993 |
Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophospham | 1993 |
Minimal residual disease detected by the PCR in chronic myeloid leukemia. Comparison of cyclophosphamide-total body irradiation and busulphan-cyclophosphamide bone marrow transplantation conditioning.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Female; H | 1993 |
Circulating colony-forming units of granulocytes/monocytes in patients with chronic myeloid leukemia before and during busulfan treatment.
Topics: Adult; Busulfan; Colony-Forming Units Assay; Female; Granulocytes; Hematopoiesis; Humans; Leukemia, | 1995 |
Karyotype conversion in two patients with chronic myeloid leukaemia after busulphan-induced marrow hypoplasia.
Topics: Adult; Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Southern; Bone Marrow Diseases; B | 1996 |
Abberant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-alpha.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; | 1996 |
Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1996 |
A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone.
Topics: Adult; Antineoplastic Agents, Alkylating; Blood; Bone Marrow; Busulfan; Humans; Karyotyping; Leukemi | 1996 |
Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia.
Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Female; Graft Survival; Hematopoietic Stem Cell | 1996 |
Interferon therapy, but not busulfan restores normal-sized megakaryopoiesis in CML--a comparative histo- and immunomorphometric study.
Topics: Adult; Aged; Antigens, CD; Biopsy, Needle; Bone Marrow; Busulfan; Female; Humans; Image Cytometry; I | 1996 |
[A modern therapeutic strategy in Ph-positive chronic myeloleukemia].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1996 |
Successful autografting in chronic myelogenous leukaemia using Philadelphia negative blood progenitor cells mobilized with rHuG-CSF alone in a patient responding to alpha-interferon.
Topics: Adolescent; Busulfan; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Ce | 1997 |
Effects of interferon treatment on the macrophage population in the bone marrow of patients with Ph1+-CML.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Bone Marrow; Bone Marrow Examination; Busulfa | 1996 |
The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 1996 |
[Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Combined Modality Therapy; Drug Administration S | 1996 |
Apoptosis and proliferation (PCNA labelling) in CML--a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Bone Marrow; Busulfan; Cell Division; Female; F | 1997 |
Busulfan alone as cytoreduction before autografting for chronic myelogenous leukemia.
Topics: Adult; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BC | 1998 |
Kaposi's sarcoma following long-term immunosuppressive therapy: clinical, histologic, and ultrastructural study.
Topics: Aged; Busulfan; CD4-CD8 Ratio; Diagnosis, Differential; Fatal Outcome; Humans; Immunocompromised Hos | 1998 |
[Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence].
Topics: Adult; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Graft | 1998 |
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; | 1998 |
Foetal liver infusion in a chronic myeloid leukemia patient with busulphan toxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Fetus; Humans; Leukemia, Myelogenous, Chronic, B | 1998 |
Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1998 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Primary Sjögren's syndrome followed by chronic myelogenous leukemia: a case report with a ten year history.
Topics: Adult; Antibodies, Antinuclear; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Fatal Outco | 1998 |
Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1998 |
Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
Topics: Acute Disease; Adult; Blast Crisis; Bone Marrow; Busulfan; Diagnosis, Differential; Female; Fusion P | 1999 |
A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclosporine; Disease-Free Survival | 1999 |
[Interferon-alpha in the treatment of chronic myeloid leukemia].
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Age | 1999 |
The impact of obesity and disease on busulfan oral clearance in adults.
Topics: Administration, Oral; Adolescent; Adult; Body Mass Index; Body Surface Area; Body Weight; Busulfan; | 1999 |
Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Chromosome Aberrations; Chromo | 1999 |
[Alpha-interferons in the treatment of patients with chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busu | 1999 |
Sideroblastic anemia following treatment of chronic myeloid leukemia with busulfan.
Topics: Aged; Anemia, Sideroblastic; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Leukemia, | 2000 |
Chronic myelogenous leukemia in chronic phase for 16 years: ongoing hematological remission and late minor cytogenetic response under minimal interferon maintenance therapy.
Topics: Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Cytogenetics; Female; Humans; Hydroxyurea; | 1999 |
[The analysis of failures in the treatment of children with chronic myelocytic leukemia in the studies of Polish pediatric leukemia/ lymphoma group].
Topics: Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; C | 1998 |
Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord blood.
Topics: Antigens, CD; Antigens, CD34; Antilymphocyte Serum; Busulfan; Cryopreservation; Female; Fetal Blood; | 2000 |
Serum vitamin E levels in patients of chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Case-Control Studies; Hum | 1999 |
Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow | 1999 |
High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience.
Topics: Adolescent; Adult; Busulfan; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplan | 2000 |
Permanent alopecia following chemotherapy and bone marrow transplantation.
Topics: Adult; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; | 2000 |
Type I and type II T cell profiles in chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Hydroxyurea; Immunity, Cel | 2000 |
Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Disease Pro | 2000 |
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
Topics: Adult; Antineoplastic Agents; Arthritis, Psoriatic; Autoimmunity; Busulfan; Graft vs Host Disease; G | 2000 |
Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
Topics: Adult; Antigens, CD20; Antineoplastic Agents; Biopsy; Bone Marrow; Busulfan; Cohort Studies; Drug Th | 2000 |
Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Busulfan; Granulocytes; Humans; Hydroxyurea; Interferon a | 2000 |
Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients.
Topics: Adult; Bone Marrow; Busulfan; Erythroid Precursor Cells; Female; Humans; Hydroxyurea; Immunohistoche | 2001 |
Allogeneic bone marrow transplantation for chronic myeloid leukemia: a retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule; Female | 2001 |
Hydroxyurea and periodicity in myeloproliferative disease.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Busulfan; Female; Hemoglobins; Humans; Hydroxy | 2001 |
Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; | 2001 |
Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis.
Topics: Adult; Aged; Antigens, CD34; Busulfan; Cytarabine; Disease-Free Survival; Drug Administration Schedu | 2001 |
Autotransplantation for chronic myeloid leukemia: is it useful?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone | 2002 |
Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Component | 2002 |
[The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
Topics: Acute Disease; Adult; Busulfan; Cyclophosphamide; Cystitis; Disease-Free Survival; Esophagitis; Fema | 2000 |
[Observation of long-term therapeutic outcome in chronic granulocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Child; Clinical Trials as Topi | 2001 |
Busulfan-induced loss of Ph chromosome in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; DNA, Neoplasm; Female; Genes, abl; | 2001 |
Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Busulfan; Cell Division; Combi | 2002 |
[Results of treatment of children with chronic myelogenous leukaemia (CML) obtained by the Polish Paediatric Leukaemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 2000 |
Relapse of chronic myeloid leukemia (CML) in lymphoid crisis after allogeneic bone marrow transplantation for CML in chronic phase with busulfan plus cyclophosphamide regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Bu | 2002 |
Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cells.
Topics: Aged; Animals; Arsenicals; Blood Platelets; Busulfan; Cell Line; Dithiothreitol; Gene Rearrangement; | 1992 |
[Appearance of a chronic myeloid leukemia in Waldenström's macroglobulinemia].
Topics: Busulfan; Chlorambucil; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; | 1992 |
Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment.
Topics: Base Sequence; Bone Marrow; Busulfan; Cell Division; Child, Preschool; Cyclophosphamide; Fetal Blood | 1992 |
Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia.
Topics: Aged; Busulfan; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; | 1992 |
[A case of pulmonary alveolar proteinosis and disseminated atypical mycobacteriosis complicating chronic myelogenous leukemia].
Topics: Busulfan; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mycobacteri | 1992 |
Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning.
Topics: Adolescent; Adult; Bone Marrow Cells; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Fe | 1992 |
Generalized seizures secondary to high-dose busulfan therapy.
Topics: Adolescent; Adult; Busulfan; Epilepsy, Tonic-Clonic; Female; Humans; Leukemia, Myelogenous, Chronic, | 1992 |
Trichosporon beigelii pneumonitis following busulphan-induced leucopenia.
Topics: Adult; Busulfan; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukopenia; Lung; Lung Di | 1992 |
Prognosis and therapy in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Humans; Hydroxyurea; Leukemia, Myelogenous | 1992 |
Poland's syndrome associated with chronic granulocytic leukemia.
Topics: Blood Cell Count; Busulfan; Female; Humans; Incidence; Infant; Leukemia, Myelogenous, Chronic, BCR-A | 1991 |
Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Topics: Bloodletting; Busulfan; Cause of Death; Hemorrhage; Humans; Incidence; Leukemia, Myelogenous, Chroni | 1991 |
Bestatin treatment of myelodysplastic syndromes and chronic myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Drug Therapy, Combination; Fe | 1991 |
The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Busulfan; Drug Resistance; Ge | 1990 |
Biclonal analysis of busulfan-induced sister chromatid exchange in blast crisis of Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Blast Crisis; Busulfan; Cell Cycle; Diploidy; Drug Resistance; Humans; Leukemia, Myelogenous, Chroni | 1991 |
[Combination therapy of chronic myelogenous leukemia with busulfan and bestatin].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; | 1991 |
Cyclic oscillations of leucocyte counts in chronic myeloid leukaemia.
Topics: Busulfan; Hemoglobins; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukoc | 1991 |
Bone marrow transplantation for leukemia after conditioning with busulfan and cyclophosphamide. Bone marrow morphology in the early recovery phase.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpla | 1991 |
Chronic myelocytic leukaemia with unusual (27 years) complete remission terminating in acute undifferentiated leukaemia: a clinical and karyotypic study.
Topics: Busulfan; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; T | 1991 |
Chronic granulocytic leukaemia. A study of 160 cases.
Topics: Adolescent; Adult; Aged; Blast Crisis; Busulfan; Female; Follow-Up Studies; Hepatomegaly; Humans; In | 1990 |
Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child, Presch | 1990 |
In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients.
Topics: Antineoplastic Agents; Busulfan; Cell Survival; Colony-Forming Units Assay; DNA Damage; Dose-Respons | 1990 |
Pulmonary alveolar proteinosis and disseminated atypical mycobacteriosis in a patient with busulfan lung.
Topics: Adult; Autopsy; Busulfan; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Lung Disea | 1990 |
Idiopathic portal hypertension associated with cytotoxic drugs.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hodgkin Disease; Humans; Hy | 1990 |
The combined use of busulfan and hydroxyurea in the treatment of chronic myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Hydroxyurea; Leukemi | 1990 |
Sequestration of Philadelphia chromosome-positive cells in the bone marrow of a chronic myeloid leukemia patient in very prolonged remission.
Topics: Bone Marrow; Busulfan; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Po | 1990 |
The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Female; Humans; Interferon alpha-2; Interferon T | 1990 |
Gastrointestinal cancer in patients with chronic myeloid leukemia on busulphan treatment.
Topics: Busulfan; Female; Gastrointestinal Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 1990 |
Current treatment of chronic myelogenous leukemia.
Topics: Blast Crisis; Bone Marrow Transplantation; Busulfan; Humans; Hydroxyurea; Interferons; Leukemia, Mye | 1989 |
Allogeneic bone marrow transplantation from HLA-identical siblings following conditioning with busulfan and cyclophosphamide. First results.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; | 1989 |
[Chronic myeloid leukemia and carcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Busulfan; Cyproterone; Cyproterone Acetate; Humans; Leuk | 1989 |
Marrow aplasia developing 3 years after treatment with busulphan for chronic myeloid leukaemia.
Topics: Adult; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chr | 1989 |
Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chronic Disease; Combined Modality | 1989 |
Chronic myelogenous leukemia following radiation therapy for testicular seminoma.
Topics: Adult; Busulfan; Combined Modality Therapy; Dysgerminoma; Humans; Leukemia, Myelogenous, Chronic, BC | 1989 |
Pericardial fibrosis following busulfan treatment.
Topics: Busulfan; Fibrosis; Heart Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; | 1989 |
Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukaemia in accelerated or blastic phase.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Female; Humans; L | 1989 |
Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation.
Topics: Bone Marrow; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Evaluation Studies as Topic; H | 1989 |
[Appearance of chromosomally normal hemopoiesis during busulfan-induced remission in a case of Ph1 positive chronic myelogenous leukemia].
Topics: Adult; Busulfan; Female; Hematopoiesis; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL | 1989 |
[Recent progress in the treatment of hematological malignancies. IV. Chronic myelocytic leukemia].
Topics: Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Humans; Interferon Type I; Leukemi | 1989 |
[A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan].
Topics: Adolescent; Adult; Bone Marrow; Busulfan; Female; Humans; Hyperplasia; Leukemia, Myelogenous, Chroni | 1989 |
[Bone marrow aplasia without blast crisis in a case of CML of 10-year survival].
Topics: Adult; Anemia, Aplastic; Blast Crisis; Bone Marrow; Busulfan; Humans; Leukemia, Myelogenous, Chronic | 1989 |
Antitumor activity and neutrophil-selective hematopoietic toxicity of busulfan analogs in mice.
Topics: Alkanesulfonates; Animals; Antineoplastic Agents; Busulfan; Female; Hematopoiesis; Hydrocarbons, Flu | 1988 |
Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Division; Cell Line; Drug Synergism; | 1989 |
Prolonged survival in chronic granulocytic leukaemia.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Follow-Up Studies; Humans; | 1988 |
[Therapy of chronic myeloid leukemia with interferon].
Topics: Adult; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Interferon alpha-2; I | 1988 |
Expression of messenger RNA for GM-CSF by blood mononuclear cells after allogeneic bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Northern; Bone Marrow Transplantation; Bus | 1988 |
Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1987 |
Busulphan/cyclophosphamide for CML.
Topics: Adolescent; Busulfan; Cyclophosphamide; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ma | 1988 |
Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
Topics: Antibody Formation; Busulfan; Combined Modality Therapy; Cross Reactions; Drug Resistance; Humans; I | 1988 |
Subcutaneous leukaemic deposit in chronic myelogenous leukaemia--course and histological appearance.
Topics: Busulfan; Female; Humans; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; | 1973 |